Stockwinners Market Radar for November 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:33 EDT Garth Brooks to headline first Amazon Music Live concert on Black Friday - Amazon Music "announced that Garth Brooks, the best-selling solo artist in U.S. history, will headline the first-ever Black Friday Amazon Music Live, or AML, special on November 24. Livestreamed from the grand opening of Brooks' new Nashville bar, Friends in Low Places Bar & Honky-Tonk, the AML special will give Brooks' millions of fans around the globe a front-row seat for one of his famed "Dive Bar" concerts. Fans will be able to tune into the AML preshow hosted by Kelly Sutton and Amber Anderson, the hosts of Country Heat Weekly, the original podcast from Amazon Music that brings listeners the latest news and interviews from the biggest names in country music. The preshow broadcast will feature interviews, special guests, and other surprises, and will air on the Amazon Music channel on Twitch starting at 6 p.m. EST. "

18:37 EDT e.l.f. Beauty CEO: Highly bullish we can double our market share over time - In an interview on CNBC's Mad Money, Tarang Amin said the company has been taking its marketing spend up recently because it's working.

17:51 EDT Apple says 'investing quite a bit' in generative AI

17:46 EDT Warrantee receives Nasdaq delisting determination, plans to appeal - Warrantee announced that it received a staff determination letter on October 27 from the Listing Qualifications Department of Nasdaq notifying the company of the determination from the Nasdaq staff to delist the company's securities from The Nasdaq Stock Market because it had not filed its Form 20-F for the period ended March 31 and is not in compliance with Nasdaq's filing requirements for continued inclusion set forth in Nasdaq Listing Rule 5250. Nasdaq explained in the letter that the company's noncompliance with the first required periodic report after listing raised questions regarding the company's ability and readiness to be a Nasdaq listed company. This announcement is made in compliance with Nasdaq Listing Rule 5810, which requires prompt disclosure of receipt of a deficiency notification. Pursuant to the letter, unless the company requests an appeal of the staff's determination, trading of the company's American Depositary Shares will be suspended at the opening of business on November 7 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the company's securities from listing and registration on Nasdaq. The letter stated that the company may appeal Staff's determination to a Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A request for a hearing will stay the suspension of the company's securities for a period of 15 days from the date of the request. The letter also stated that when the company requests a hearing, it may also request a stay of the suspension pending the hearing. The company intends to request a hearing to appeal the staff's delisting determination and an extended stay by 4:00 p.m. on November 3.

17:41 EDT SEC fines Royal Bank of Canada $6M to settle internal control violations - The Securities and Exchange Commission announced that Canada's largest bank, Royal Bank of Canada, will pay a $6M penalty to settle charges that it violated the books and records and internal accounting controls provisions of the securities laws relating to its accounting for its costs of internally developed software. The SEC's order finds that, from 2008 through 2020, Royal Bank of Canada's accounting controls failed to ensure that the firm accurately accounted for its internally developed software project costs. The order finds that, for a portion of its internally developed software projects, Royal Bank of Canada applied a single rate to determine how much of those projects' costs to capitalize, but it lacked a reliable method for determining the appropriate rate to apply, in part because it could not adequately differentiate between capitalizable and noncapitalizable costs. This resulted in, among other things, the bank using the same capitalization rate each year without a sufficient basis and capitalizing certain costs that were ineligible under the appropriate accounting methodology. "Royal Bank of Canada had longstanding internal accounting control deficiencies that it failed to adequately address," said Nicholas P. Grippo, Regional Director of the Philadelphia Regional Office. "Properly functioning internal accounting controls are a front-line defense and help ensure accurate financial disclosures-the backbone of our capital markets." Reference Link

17:40 EDT Apple says FX 'continues to be a drag' both sequentially and y/y

17:39 EDT Kratos Defense announces XQ-58A Valkyrie completes test flight - Kratos Defense announced the Marine Corps XQ-58A Valkyrie, a highly autonomous, low-cost tactical unmanned air vehicle successfully completed its first test flight October 3, at Eglin Air Force Base, Florida. Kratos partnered with the Marine Corps, the Office of the Undersecretary of Defense for Research and Engineering, the Naval Air Systems Command and Naval Warfare Center Aircraft Division to facilitate the ongoing research, development, test and evaluation of the Marine Corps XQ-58A Valkyrie.

17:34 EDT Mistras sees 15% reduction in administrative headcount, 12M in 2024 cost savings - Mistras provided an update on the status of Project Phoenix, the company's program to increase Income from operations through reductions in corporate administrative overhead and enhancements to pricing. The company said, "The following is a brief overview of the additional actions being implemented as a result of Project Phoenix: The Company has developed and will be further enhancing a proactive structural pricing strategy intended to address inflationary costs experienced in our business. The Company's goal is to reduce selling, general, and administrative expenses ("SG&A") to approximately 21% of total revenues by the end of 2024, primarily through a rationalization of the overhead workforce, including a targeted 15% reduction in administrative headcount, without adversely impacting the Company's technician base or ability to support operations and service its customers. As part of the Company's transformation plan to improve shareholder value by lowering SG&A, improving free cash flow, and accelerating growth, the Board made recent changes to senior leadership within the Company to further strengthen the organization and enhance the execution of the various initiatives comprising Project Phoenix... The actions completed by the Company during the nine months ended September 30, 2023, are expected to yield annualized projected 2024 cost savings of approximately $12 million, of which approximately $7 million is expected to be realized in 2023, due to actions completed as of September 30, 2023 including the transformation of the Company's Products and Systems segment announced on October 2, 2023, in addition to other ancillary initiatives. Subsequent to September 30, 2023, and prior to the release of the Company's third quarter 2023 financial results, the Company completed further actions that are expected to yield incremental annualized projected 2024 cost reductions of approximately $12 million including the optimization of North America administrative support functions, of which approximately $2 million is expected to be realized in the fourth quarter of 2023. These initiatives, including those previously disclosed, combine to yield a projected annualized cost savings of approximately $24 million, of which approximately $9 million is expected to be realized in fiscal 2023, with the full $24 million benefit expected to be realized in fiscal 2024. This would result in an approximate $15 million incremental benefit from Project Phoenix in 2024 as compared to 2023. The Company will be working to finalize additional opportunities in the fourth quarter of 2023... In addition to the aforementioned projected cost savings, the Company is focused on the implementation of strategic price increases which will improve revenue in 2023 by approximately $1 million and are expected to provide an additional $6 million revenue benefit in 2024."

17:30 EDT Paramount says Q4 D2C losses to be similar to year-ago levels - CFO Naveen Chopra stated: "Looking ahead, we expect strong D2C revenue growth with another quarter of healthy sub growth. That said, Q4 D2C losses will be similar to the year ago period. This reflects higher sports costs as well as higher marketing costs to support our broader geographic footprint as most of our Western European launches occurred late in the fourth quarter of 2022. Nonetheless, as I noted earlier, we now expect full year D2C losses in 2023 to be lower than 2022. And meaning we are ahead of plan in moving the D2C business toward profitability. The ongoing execution of our streaming strategy will yield further improvement in 2024 as we continue to drive subscriber growth user engagement and Paramount+ global ARPU growth in excess of 20%... Looking ahead to Q4, advertising growth will continue to be impacted by a sizable decline in political advertising. We're seeing modest improvement in domestic linear advertising, but we continue to deal with strike impact and international weakness, which will limit improvement in the year-over-year trend. Shifting gears a bit, I'd like to provide additional detail regarding the financial impact of the strikes. In Q3, total company OIBDA included nearly $60 million of strike-related idle costs. These are incremental expenses incurred to retain production capabilities while the strike is ongoing. These costs impacted both our TV media and filmed entertainment segments. We expect to incur additional strike-related idle costs in Q4."

17:28 EDT Kronos Bio to reduce workforce by 19% in restructuring - Kronos Bio announced a plan to optimize its resource allocation, restructure, and contain costs in light of the positive preliminary safety and efficacy clinical data from its Phase 1/2 study of KB-0742. This plan positions the company to maximize the potential of KB-0742 while continuing to advance the development of lanraplenib, currently in the dose escalation portion of a Phase 1b/2 study. The company will also focus its discovery efforts on maturing projects and its Genentech collaboration activities. Kronos Bio expects that these restructuring efforts, which include a 19% reduction in force, will extend its cash runway into 2026.

17:26 EDT Paramount says company advancing toward Streaming profitability - CEO Robert Bakish stated: "Paramount Plus crossed 63 million subscribers, and we delivered 38% D2C revenue growth aided by a successful price increase. We also narrowed our D2C adjusted OIBDA losses by over 30%. In fact, we now believe 2022 was our year of peak streaming investment meaning D2C losses in 2023 will be lower than in 2022. We're clearly advancing on the path to streaming profitability and this continued D2C improvement will be a key driver of the total company earnings growth we expect next year. Related to that, our integration of Paramount+ and Showtime continues to deliver as we expected... Recent negotiations in the industry have raised questions about whether the hard bundling of streaming and pay TV will become the norm in the U.S. and what that could mean for companies like ours. The reality is, operators have different priorities, but we've shown that we can adapt our partnerships to accomplish common objectives. As we go forward, it is possible that some of our partners will embrace the strategy that more tightly integrates DTC into the Pay TV bundle. And we expect that if they do, the bundles would have many of the same advantages we've observed in the various hard bundles we've deployed internationally, namely a dramatically lower cost of acquisition and improvement in streaming churn, and it may improve TV ecosystem trends as well." Comments taken from Q3 earnings conference call.

17:24 EDT Apple says 'particularly pleased' with revenue in emerging markets - Says expanding direct presence in these markets.

17:19 EDT Burlington Stores to replace Envestnet in the S&P 400 at open on 11/7 - Burlington Stores (BURL) will replace Envestnet (ENV) in the S&P MidCap 400, and Envestnet will replace Hostess Brands (TWNK) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, November 7. S&P 500 constituent The J. M. Smucker Co. (SJM) is acquiring Hostess Brands in an exchange offer expected to be completed on or about that date pending final conditions.

17:13 EDT Apple says reached all-time revenue record in India in Q4 - Says iPhone reached quarterly revenue record in mainland China. Says achieved quarterly records in many markets in Q4. Says reviews for iPhone 15 family "off the charts." Says innovating at a "tremendous pace." Plans to make every product carbon neutral by end of the decade. Comments taken from Q4 earnings conference call.

17:02 EDT Starbucks plans to expand store footprint to 55,000 by 2030 - As part of its new long-term growth strategy, Starbucks announced a plan to expand its global store footprint to 55,000 by 2030 - an average of 8 new stores a day and bolstered by further expansion of digital platforms across all licensed partners globally. "Over the past five years, we have opened 9,000 stores - 7,000 of which were outside of the U.S.," said Michael Conway, group president, International and Channel Development. "We will become truly global as we create the surround sound of omni-channel strategies in the 86 markets where we sell Starbucks Coffee." Starbucks China is uniquely positioned to support the growth opportunities the market presents. The business will continue driving comps in existing stores through global and locally relevant innovation across dayparts and across channels in beverages and food. Additionally, Starbucks will continue to invest in the expansion of Starbucks Rewards. The company also believes there is significant headroom in new store expansions with attractive returns, including continuing to infill existing cities with purpose-defined store formats, while entering more new county cities. Finally, Starbucks will continue to invest in digitalization across supply chain and store operations that fuel productivity and efficiency, while driving innovation with customers, partners, coffee and sustainability. "We just concluded a watershed year in China, where we put the pandemic behind us, and built growth momentum for the future," said Belinda Wong, chairwoman and co-ceo of Starbucks China. In commenting on the overall international business, Wong noted that the omni-channel strategy "gives us great confidence and high ambition for our international business, fueling nearly 1/3 of the earnings growth potential of Starbucks over the long-term."

17:02 EDT Starbucks seeks to double global Rewards members within next five years - As part of its new long-term growth strategy, Starbucks unveiled a new phase in the acceleration of its digital flywheel. Strengthening its digital leadership with a strategy aimed to: Double global Starbucks Rewards with another 75 million members - the company's most frequent customers - within the next five years; Building on its highly successful program with Delta Airlines, the company also intends to extend the benefits that Starbucks Rewards provides to existing and new customers with additional 'Rewards Together' partnerships - with a financial institution and a hospitality partner - within the next 6 months; "Starbucks has direct, digital relationships with hundreds of millions of customers," said Brady Brewer, executive vice president and chief marketing officer. "Our ambition is to know every customer, personalize their experience and make Starbucks effortless. We have a clear and compelling roadmap, the acceleration has already started, and we will extend our digital leadership globally." In addition to extending its digital and tech leadership through personalization and customization, the company is resetting its tech architecture, accelerating the introduction of new features, building on its distinctive Deep Brew platform capabilities. Starbucks also announced three new technology collaborations it intends to execute in order to enhance the customer and partner experience: The partnership with Microsoft will extend through collaboration in its innovation lab to marry industry leading generative AI capabilities to take product development and personalization to the next level; Collaborating with Apple products in our first Green Apron Innovation store to experiment and refine technology to assist partners across the globe; Reimagining the customer in-store experience with Amazon One and Just Walk Out technology.

17:00 EDT Starbucks announces Triple Shot Reinvention strategy - Starbucks announced its long-term growth strategy, Triple Shot Reinvention with Two Pumps, to elevate the brand, strengthen and scale digital, further expand globally, identify opportunities within and outside the store for efficiencies, and reinvigorate the partner (employee) culture. The strategy builds on the significant business momentum from the past year, while laying out a roadmap for how the company will deliver long-term, sustainable growth and outsized returns to partners, customers, and shareholders. "I am immensely proud of the work we have done so far in reinventing and re-founding the company for its next phase of growth. I am excited about our multiple paths to revenue growth and earnings, which should give you confidence in our ability to meet our goals," said Laxman Narasimhan, chief executive officer of Starbucks as part of the company's presentation to investors in New York City. "I am honored to be leading this talented group of over 450,000 green apron partners, including this executive leadership team, to deliver human connection more broadly around the world for the benefit of us all." With the U.S. store count slated to reach more than 16,300 - with a 4 percent net new store growth planned in FY24 and an aspiration to reach 20,000 over the long term - the company will leverage the vast channels available to meet the evolving needs of customers and further elevate the brand. Starbucks will focus on running better stores through a stronger operating foundation. The company will grow the portfolio with more purpose-defined stores and accelerated renovations. "We see an opportunity to better leverage our footprint to serve the evolving needs of our customers. Innovation in our store formats, to purpose defined stores like pick-up, drive-thru only, double-sided drive-thru, and delivery-only allows us to better meet our customers where they are at through differentiated experiences," said Sara Trilling, executive vice president and president of Starbucks North America. "To capture that demand we will build more new stores - with new formats, in new cities and cities we're already in. To be clear, Starbucks has not saturated the U.S. market." Additionally, the brand will be elevated through further product innovation. The company will continue to grow coffee and its core menu through customization and personalized marketing - adding popular beverage innovations to the core line up - which now accounts for 85 percent of net beverage sales. The company will also drive innovation through two specific areas of focus: targeted dayparts and growing food attach with all-day breakfast and all-day snacks.

16:56 EDT Castle Biosciences announces new data on pipeline test ability - The company states: "Castle Bioscience announced new data showing the ability of its pipeline test in development to distinguish between responders and non-responders to an atopic dermatitis (AD) therapy and also distinguish between AD, psoriasis (PSO) and mycosis fungoides (MF) skin lesions. The goal of Castle's innovative pipeline initiative is to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe AD, PSO and related conditions. Additional updates regarding development of this pipeline program are expected in 2024."

16:45 EDT Honeywell unit selects Triumph Group for next-gen Electronic Control Unit - Triumph Group (TGI) announced that its Systems, Electronics and Controls business has been selected by Honeywell Aerospace (HON) to provide the next-generation, engine-mounted Electronic Control Unit for future Auxiliary Power Unit models for both commercial and non-commercial aircraft. Utilizing proprietary technology, TRIUMPH's team of experienced control engineers are designing and manufacturing an ECU for Honeywell's next generation APU with cutting-edge processors which meet the latest cybersecurity requirements.

16:43 EDT Health Catalyst announces multi-year contract with Accountable Health Partners - Health Catalyst announced a comprehensive, multi-year strategic partnership with Accountable Health Partners, a clinically integrated network with a proven record of improving quality outcomes and delivering value to 400,000 patients in the Greater Rochester area. The clinically integrated network has nearly 3,000 physician and advanced practice providers and twelve of the region's leading hospitals.

16:41 EDT PagerDuty to acquire Jeli, terms not disclosed - PagerDuty announced it has signed a definitive agreement to acquire Jeli, Inc. to transform operations with an enterprise-grade, all-in-one incident management solution. The addition of Jeli's capabilities to the PagerDuty Operations Cloud will further strengthen its value as a system of action, going beyond response to drive long-lasting improvements in operational maturity. The PagerDuty Operations Cloud combines Incident Management, AIOps, Automation and Customer Service Operations in a flexible, easy-to-use platform designed for mission-critical, time-sensitive, high-impact work across IT, DevOps, security and business teams. "Every company's customers are digitally fluent, yet most company's operations are analog, manual and command and control. This chasm gets wider as technical complexity grows, making operational resilience and delightful customer experiences harder to deliver," said Jennifer Tejada, Chairperson and CEO, PagerDuty. "With Jeli, our combined offering will empower executives to make faster, more effective operational decisions to speed and expand innovation while minimizing the costs and risk of operational failure. With Jeli, PagerDuty becomes a cloud-first, automated Incident Management solution that scales securely and reliably for large enterprises. We are thrilled to welcome Nora Jones and the Jeli team to PagerDuty."

16:39 EDT Floor & Decor reports Q3 SSS down 9.3%

16:36 EDT Royal Bank of Canada charged by SEC with internal accounting controls violations - The Securities and Exchange Commission announced that Canada's largest bank, Royal Bank of Canada, will pay a $6M penalty to settle charges that it violated the books and records and internal accounting controls provisions of the securities laws relating to its accounting for its costs of internally developed software. The SEC's order finds that, from 2008 through 2020, Royal Bank of Canada's accounting controls failed to ensure that the firm accurately accounted for its internally developed software project costs. The order finds that, for a portion of its internally developed software projects, Royal Bank of Canada applied a single rate to determine how much of those projects' costs to capitalize, but it lacked a reliable method for determining the appropriate rate to apply, in part because it could not adequately differentiate between capitalizable and noncapitalizable costs. This resulted in, among other things, the bank using the same capitalization rate each year without a sufficient basis and capitalizing certain costs that were ineligible under the appropriate accounting methodology. Without admitting or denying the findings, Royal Bank of Canada has agreed to cease and desist from committing or causing any violations or any future violations of these provisions. Royal Bank of Canada also agreed to pay a $6M civil penalty, offset by amounts paid to Canadian regulatory authorities as a result of the same conduct. The SEC considered Royal Bank of Canada's remedial acts in determining to accept the settlement.

16:35 EDT Parts iD receives non-compliance notice from NYSE American - PARTS iD announced that it has received written notice from the NYSE American LLC stating that it is not in compliance with the continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because the Company's common stock was selling for a substantial period of time at a low price per share. The Notice stated that the Company's continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which NYSE American has determined to be no later than April 27, 2024. However, NYSE American may take an accelerated delisting action that would pre-empt the cure period in the event that the common stock trades at a level viewed to be abnormally low.

16:34 EDT Apple CEO highlights September quarter revenue record for iPhone - Apple CEO Tim Cook said in today's earnings statement, "Today Apple is pleased to report a September quarter revenue record for iPhone and an all-time revenue record in Services. We now have our strongest lineup of products ever heading into the holiday season, including the iPhone 15 lineup and our first carbon neutral Apple Watch models, a major milestone in our efforts to make all Apple products carbon neutral by 2030."

16:34 EDT Apple falls 2% to $174.00 after Q4 report

16:33 EDT Apple Q4 Wearables, Home and Accessories revenue $9.32B vs. $9.65B last year

16:32 EDT Apple reports Q4 Mac revenue $7.61B vs. $11.51B last year

16:31 EDT Apple declares quarterly dividend of 24c per share - Apple's board of directors has declared a cash dividend of 24c per share of the company's common stock. The dividend is payable on November 16, to shareholders of record as of the close of business on November 13.

16:27 EDT Rivian Automotive hires Georgia plant manager - Rivian Automotive announced that Arnhelm Mittelbach has joined Rivian as its first Georgia Plant Manager. This is a significant addition as Rivian continues to progress on its second manufacturing facility that will be focused on the next generation of Rivian vehicles. Mittelbach started his role on November 1, reporting directly to Chief Operations Officer Frank Klein. Mittelbach is an experienced automotive leader with more than 20 years tenure at Mercedes-Benz, including Plant Manager in East London, South Africa, President and CEO of Mercedes-Benz Vans in Charleston, South Carolina, and a variety of manufacturing leadership roles across Germany. "We are thrilled to welcome Arnhelm to the Rivian Operations team," said Rivian's Chief Operations Officer Frank Klein. "He brings tremendous experience in ramping up new factories and launching new products. Beyond his significant manufacturing prowess, Arnhelm also has a background in other areas, such as HR, making him a well-rounded leader to advance our team in Georgia."

16:25 EDT Puma Biotechnology sees Q4 product revenue $56M-$59M - Sees FY23 product revenue $206M-$209M.

16:22 EDT Atlassian backs FY24 cloud revenue growth view up 25%-30% - In FY24: Cloud revenue growth year-over-year is expected to be in the range of 25% to 30%. Data Center revenue growth year-over-year is expected to be approximately 31%. Gross margin is expected to be approximately 81.0% on a GAAP basis and approximately 83.5% on a non-GAAP basis. Operating margin is expected to be approximately (5.5%) on a GAAP basis and approximately 20.0% on a non-GAAP basis.

16:19 EDT Ryan Specialty updates ACCELERATE 2025 program - "The Company is updating the ACCELERATE 2025 restructuring program as we have identified additional opportunities to drive continued growth and innovation, deliver sustainable productivity improvements over the long term, and accelerate margin improvement," Ryan Specialty said. "The updated program will result in approximately $90 million of cumulative one-time charges through 2024, and we expect the program to generate annual savings of approximately $50 million in 2025."

16:17 EDT nLight announces expansion of HELSI contract award to $171M - nLIGHT "announced the award of additional options that more than double the previously-announced contract to produce a High Energy Laser prototype as part of the second phase of the DoD's Office of the Under Secretary of Defense, Research & Engineering High Energy Laser Scaling Initiative, or HELSI. The original phase two award announced in May 2023 was for $86 million, and the exercise of the additional options announced today brings the total value of the award to nLIGHT to $171 million."

16:15 EDT Figs announced the appointment of Marte to board of directors - FIGS (FIGS) announced the appointment of Mario Marte, former Chief Financial Officer of Chewy, (CHWY), to its Board of Directors, effective November 3, 2023. Mr. Marte joins the Board as an independent director and has also been appointed to the Board's Audit Committee.

16:12 EDT Block sees FY24 adjusted EBITDA $2.4B, adjusted operating income $875M

16:11 EDT WW down 15% after reporting Q3 earnings, FY23 guidance

16:02 EDT Expedia announces $5B share repurchase authorization - Expedia Group announced that its Board of Directors has approved a $5 billion share repurchase authorization of the company's common stock, which is effective immediately and is in addition to the company's currently outstanding share repurchase authorization. "The decision to approve a new $5 billion share repurchase authorization reflects our confidence in the long-term outlook of our company and the cash generating power of our business, as well as our commitment to maximizing returns for our shareholders," said Peter Kern, Vice Chairman and CEO, Expedia Group.

15:56 EDT Vuzix announces partnership with EDAP TMS - Vuzix announced a partnership with EDAP TMS SA, whereby Vuzix will supply its M400 smart glasses to be used in conjunction with EDAP's Focal One Robotic High Intensity Focused Ultrasound Platform for device setup, troubleshooting, and applications use. EDAP plans to ship a pair of M400 smart glasses with every HIFU unit they ship, Vuzix said.

15:47 EDT Bill Gross says he's buying Truist, Citizens, KeyCorp, First Horizon shares - Truist (TFC), Citizens Financial (CFG), KeyCorp (KEY), and First Horizon (FHN) were all rising in afternoon trading after Pimco co-founder Bill Gross said in a post on X, formerly Twitter, that the regional bank falling knife has "hit bottom," and that he's buying the aforementioned bank stocks. Gross said that the treasury yield picture is "still uncertain," but noted that the best strategy is to invest in the 2/10 curve continuing to "disinvert." Reference Link

15:21 EDT Realtors group CEO leaves amid 'inflated' commissions verdict, interim appointed - National Association of Realtors, announced earlier on Thursday, that "Nykia Wright has been appointed its interim Chief Executive Officer, starting November 20. Bob Goldberg, who announced his planned retirement in June of this year, will serve as an executive consultant to NAR to help support the transition. As previously announced, NAR is conducting a comprehensive search process to identify a permanent CEO."...Company in the realtors space include: Redfin (RDFN), Zillow (Z), Lemonade (LMND), Opendoor Technologies (OPEN), Re/Max Holdings (RMAX). Opendoor Technologies (OPEN), and Compass (COMP). Reference Link

14:57 EDT Plus Therapeutics gets orphan designation for breast cancer treatment - Plus Therapeutics' treatment of breast cancer with leptomeningeal metastases was granted FDA orphan designation, according to a post to the agency's website. Reference Link

14:13 EDT Six Flags holder Land & Buildings says merger does not maximize value - Land & Buildings Investment Management, a shareholder of Six Flags Entertainment (SIX), issued a comment on the company's proposed merger with Cedar Fair (FUN): "The proposed merger of Six Flags and Cedar Fair does not maximize value for all shareholders and there are better alternatives available. We believe the right path forward is to monetize the Company's real estate, which alone is likely worth nearly $30 per share based on inquiries we have received from interested third parties. We plan to explore all options to maximize value for shareholders and do not intend to support the merger as currently structured."

13:51 EDT Uber to pay $290M, Lyft $38M in settlements with New York AG - New York Attorney General Letitia James announced two settlements totaling $328M with Uber (UBER) and Lyft (LYFT) "for cheating drivers out of hundreds of millions of dollars." The settlements resolve multi-year investigations into Uber and Lyft, which found that the companies' policies withheld hard-earned pay from drivers and prevented them from receiving valuable benefits available under New York labor laws, James said in a statement. Uber will pay $290M and Lyft will pay $38M into two separate settlement funds which will be entirely distributed to current and former drivers. Reference Link

13:16 EDT Constellation Brands trading resumes

13:08 EDT Virgin Galactic reports sixth successful spaceflight in six months - Virgin Galactic announced the completion of its sixth space mission in six months and tenth to date. The "Galactic 05" mission saw Virgin Galactic's spaceship converted into a suborbital lab for space-based scientific research for the second time. Michael Colglazier, CEO of Virgin Galactic, said: "Providing researchers with reliable and repeatable access to a high-quality microgravity environment is vital to our mission of expanding human knowledge and enabling scientific discoveries. We are proud to support the work of the Southwest Research Institute and International Institute for Astronautical Sciences with today's flight, and we will use insights from the mission to enhance the research capabilities of our future Delta-class spaceships. We look forward to playing an increasingly important role in space research in the years ahead."

13:06 EDT Constellation Brands announces additional $2B share repurchase authorization

13:04 EDT Constellation targeting low double-digit diluted EPS growth ex-Canopy EIE - Constellation Brands said it will "reinforce its strategic foundation for continued growth" at its investor day hosted at 2:00 p.m. EDT and the stock was halted ahead of the start of the event. "Strong outlooks in both the Beer and Wine & Spirits Business give the company confidence to aim to deliver double-digit diluted EPS growth, excluding Canopy EIE, as part of its medium-term algorithm. In addition, the company anticipates a step-up in operating cash flow growth, which combined with optimized organic investments primarily focused on supporting incremental brewing capacity, are expected to enable the company to deliver between $10 and $12 billion in free cash flow from its fiscal year 2024 to fiscal year 2028," the company stated.

13:01 EDT Seagen says new ADCETRIS data to be featured at ASH 2023 - Seagen announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma, respectively. The data will be featured in two oral presentations at the 65th American Society of HematologyAnnual Meeting & Exposition, taking place December 9-12, 2023 in San Diego. The ongoing Phase 2 clinical trial, SGN35-027, is evaluating ADCETRIS in combination with immunotherapy and chemotherapy. In addition, pre-clinical data will be presented for a next-generation novel CD30-directed antibody-drug conjugate (ADC), SGN-35C, that uses a topoisomerase I inhibitor payload. "These new data highlight our continued research and development focus on novel combinations to treat Hodgkin lymphoma and on next-generation CD30-directed therapies that aim to further improve outcomes while reducing treatment burden for patients," said Roger Dansey, M.D., President, Research and Development and Chief Medical Officer at Seagen.

12:16 EDT Mountain Crest Acquisition Corp IV trading resumes

12:04 EDT Kronos Bio presents data fom Phase 1 dose escalation portion of KB-0742 study - Kronos Bio announced the presentation of positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting in Dublin, Ireland. Today's presentation by Dr. Van Tine of Washington University School of Medicine includes clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Massachusetts in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity. Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma. KB-0742 is Kronos Bio's internally discovered, highly selective, orally bioavailable cyclin dependent kinase 9 inhibitor being developed to treat transcriptionally addicted solid tumors, including small cell lung cancer, sarcomas with transcription factor fusion genes and MYC-dependent tumors, such as triple negative breast, ovarian, and lung cancer. The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg. KB-0742 demonstrated on-mechanism single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted tumor types and exhibited a manageable safety profile, with no grade 3/4 neutropenia. KB-0742 also demonstrated dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life. The most prevalent treatment-emergent adverse events included nausea, vomiting and fatigue, all of which were grade 1/2. No grade 3/4 neutropenia was observed, and no treatment-related deaths were observed. The most common reasons for treatment discontinuation were progressive disease, TEAEs, and withdrawal of consent.

12:00 EDT First Majestic falls -14.8% - First Majestic is down -14.8%, or -77c to $4.42.

12:00 EDT Procore falls -17.2% - Procore is down -17.2%, or -$10.34 to $49.83.

12:00 EDT Shopify rises 21.7% - Shopify is up 21.7%, or $10.58 to $59.37.

11:38 EDT Bristol Myers to present research across portfolio, pipeline at ASH Meeting - Bristol Myers Squibb announced the presentation of research across its hematology and cell therapy portfolio and pipeline at the 65th American Society of Hematology Annual Meeting and Exposition, which will take place in San Diego, California from December 9 to 12, 2023. Results from 73 data disclosures across company-sponsored studies will be featured, including 22 oral presentations, showcasing BMS' commitment to delivering transformative medicines that help more patients living with blood disorders. Key data being presented by Bristol Myers Squibb and its partners at the 2023 ASH Annual Meeting and Exposition include: Cell Therapy: First disclosure of efficacy and safety data from the primary analysis of the Phase 2 TRANSCEND FL study of Breyanzi for the treatment of patients with high-risk relapsed or refractory follicular lymphoma in the second-line setting. Patient-reported outcomes and health-related quality of life data from this study will also be presented. First disclosure of Center for International Blood and Marrow Transplant Research registry data showcasing safety and efficacy of Breyanzi in relapsed or refractory large B-cell lymphoma when used in the real world. Multiple analyses from the Phase 3 KarMMa-3 study evaluating Abecma in patients with triple-class exposed relapsed and refractory multiple myeloma, including final progression-free survival data, interim overall survival data, safety profile characterization and patient-reported outcomes from extended follow-up. Updated safety and efficacy results from the Phase 1 study of GPRC5D CAR T in patients with relapsed or refractory multiple myeloma, including in patients with prior BCMA-directed therapy. Targeted Protein Degradation: First results from the Phase 1/2 CC-92480 MM-002 study evaluating CELMoDTM agent mezigdomide with dexamethasone and daratumumab or elotuzumab in patients with relapsed or refractory multiple myeloma. Updated results from the dose-escalation and dose-expansion components of the Phase 1 CC-220-DLBCL-001 study, evaluating potential first-in-class CELMoD agent golcadomide in combination with R-CHOP in previously untreated diffuse LBCL. Translational data describing a potential mechanism of reversal of T-cell exhaustion by CELMoD agents, highlighting the potential for CELMoD agents to enhance T-cell redirecting therapies. Additional Novel Treatment Modalities: Multiple presentations from the Phase 3 COMMANDS study of Reblozyl in the treatment of anemia in patients with lower-risk myelodysplastic syndromes who are erythropoiesis stimulating agent-naive, including primary analysis data, patient-reported outcomes and mutational analysis. Updated safety and efficacy data for potential best-in-class BET inhibitor BMS-986158 in combination with ruxolitinib or Inrebic in first- and second-line myelofibrosis. Updated safety and efficacy data for subcutaneous 2+1 T-cell engager alnuctamab in heavily pretreated multiple myeloma from the Phase 1 CC-93269-MM-001 study.

10:54 EDT Pfizer reports 39 presentations spanning ten medicines at ASH - Pfizer announced it will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology, or ASH, Annual Meeting and Exposition in San Diego from December 9-12. These data from 39 presentations "represent continued innovation and advancement in hemophilia," including pivotal findings for Pfizer's novel anti-tissue factor pathway inhibitor candidate marstacimab and the latest findings on a next-generation investigational treatment for sickle cell disease in GBT021601, the company stated. Pfizer will also present the latest research in blood cancer, including for ELREXFIO, a BCMA-directed bispecific antibody recently approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory multiple myeloma, or RRMM, who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. "During ASH, we are pleased to present new clinical and real-world data in multiple myeloma from our broad development program for ELREXFIO, following recent FDA accelerated approval. This includes extended efficacy and safety results from MagnetisMM-3, highlighting sustained clinical efficacy and no new safety signals after 20 months of follow-up. These data continue to support the potential of ELREXFIO as the next standard of care for patients with advanced multiple myeloma," said Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President, Pfizer.

10:42 EDT Onconova's ASH poster to focus on narazaciclib in MCL - Onconova Therapeutics announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition, taking place in San Diego, California from December 9 to 12, 2023. "The poster that we and researchers from the Josep Carreras Leukaemia Research Institute in Barcelona, Spain are presenting at ASH 2023 shows that the study of narazaciclib, either as a single agent or in combination with ibrutinib, effectively controls tumor growth in preclinical models of mantle cell lymphoma, including those that are resistant to Bruton's tyrosine kinase inhibitors, a mainstay of care for this aggressive and difficult to treat cancer. The experiments included a broad comparison of narazaciclib with three other approved cyclin-D-kinase inhibitors, used in combination with several BTKis," said Steven Fruchtman, M.D., President and CEO of Onconova.

10:25 EDT Chase doubles commitment to hire 1,000 new business bankers by 2025 - Chase intends to hire 1,000 new business bankers in local markets across the United States by 2025 to support small business owners as they continue to grow and scale their business in their communities. This new commitment builds on the firm's original goal of hiring 500 new bankers through 2024. The increased hiring commitment comes as the firm hosts its inaugural "Make Your Move Summit," a complimentary, three-day event drawing thousands of small business owners to learn from industry experts, thought leaders, and celebrities on how to start, run and grow their business.

10:14 EDT Northern Trust enters partnership with Novata - Northern Trust has reached an agreement to make available Novata's ESG data management software solution to Northern Trust asset servicing clients, following a strategic investment in the company. The addition of Novata's data management solution is an extension of Northern Trust's Whole Office strategy that will provide asset owners a clearer view of the ESG impact of private companies on investment portfolios and simplify the ESG data collection process for investors and portfolio companies. Northern Trust Whole Office facilitates client access to new technologies, services and solutions across the investment lifecycle.

10:09 EDT Myomo says CMS classifies MyoPro Orthosis under brace benefit category - Myomo announced that the Centers for Medicare & Medicaid Services published a final rule classifying the MyoPro under the brace benefit category. Braces are paid on a lump sum basis under the Social Security Act. The finalization of MyoPro's classification as a brace paid on a lump sum basis, rather than on a capped rental basis, brings Medicare payment methodology in line with how all other insurance plans currently pay for the MyoPro. This rule is expected to be published in the Federal Register on November 13, 2023 and is effective on January 1, 2024. The MyoPro has already been covered and paid on a rental basis for five Medicare beneficiaries covering all of Medicare's billing regions after review of their medical documentation. Future claims for devices delivered to patients are expected to continue to be reviewed on a claim-by-claim basis. Paul R. Gudonis, Myomo's chairman and CEO, stated, "On behalf of the many stroke survivors and others with long term muscular weakness or partial paralysis with Medicare Part B insurance, we are pleased that CMS has moved forward to facilitate access to the MyoPro brace. The MyoPro has been shown to be effective for Medicare beneficiaries with the requisite medical necessity, and this reclassification is very supportive of CMS' goal of health equity for this population."

10:03 EDT Beyond Meat further reduces workforce by 8% or 65 employees - Beyond Meat announced in its earnings report that to further reduce operating expenses, it is initiating a review of its global operations, narrowing its commercial focus to certain growth opportunities, and accelerating activities that prioritize gross margin expansion and cash generation. These efforts include the potential exit of select product lines; changes to the company's pricing architecture within certain channels; accelerated, cash-accretive inventory reduction initiatives; further optimization of the company's manufacturing capacity and real estate footprint; and a review and potential restructuring of the company's operations in China. In addition, Beyond Meat is further reducing its current workforce by approximately 65 employees, representing approximately 19% of the company's global non-production workforce, or approximately 8% of its total global workforce. In aggregate, in 2024, the reduction in force, combined with the elimination of certain open positions, is expected to result in approximately $9.5M to $10.5M in cash operating expense savings, and an additional approximately $1.0M to $2.0M in non-cash savings related to previously granted, unvested stock-based compensation which would have vested in 2024. The Company currently estimates that it will incur one-time cash charges of approximately $2.0M to $2.5M in connection with the reduction in force.

10:01 EDT Southwest signs pact with USA BioEnergy to purchase up to 680M gallons of SAF - Southwest Airlines announced an offtake agreement with USA BioEnergy for up to 680M gallons of neat sustainable aviation fuel. Over the term of the 20-year agreement, once blended with conventional jet fuel, the SAF could produce the equivalent of 2.59B gallons of net-zero1 fuel and avoid 30M metric tons of CO2. Southwest plans to begin purchasing SAF from USA BioEnergy's facility near Bon Wier, Texas, as early as 2028. Additionally, as part of the offtake agreement, Southwest and USA BioEnergy have established a long-term strategic relationship offering Southwest the opportunity to purchase up to another projected 180M gallons of SAF per year from future planned production facilities.

10:00 EDT Regal Rexnord falls -15.3% - Regal Rexnord is down -15.3%, or -$18.13 to $100.08.

10:00 EDT Procore falls -19.6% - Procore is down -19.6%, or -$11.77 to $48.40.

10:00 EDT Joby Aviation rises 21.1% - Joby Aviation is up 21.1%, or $1.13 to $6.49.

09:58 EDT ServisFirst CFO William Foshee to retire, Kirk Pressley to succed - ServisFirst announced the retirement of founding CFO, William Foshee, effective after the filing of the Form 10-K in February of 2024. Kirk Pressley has been appointed as successor to the role of CFO. Kirk Pressley joined ServisFirst Bancshares in July of 2023 and is the former CFO of BBVA Compass Bancshares.

09:54 EDT Charles River Associates increases quarterly dividend 17% to 42c per share - Charles River Associates announced that its board of directors has declared a 17% increase in the quarterly cash dividend from 36c to 42c per common share to be paid on December 8 to shareholders of record of CRA's common stock as of the close of business on November 28. The company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain subject to the discretion of CRA's board of directors.

09:53 EDT Cheniere Energy subsidiary enters LNG SPA with Foran Energy - Cheniere Energy announced that Cheniere's subsidiary, Cheniere Marketing, has entered into a long-term liquefied natural gas sale and purchase agreement, or SPA, with Foran Energy Group. Under the SPA, Foran has agreed to purchase approximately 0.9M tons per annum of LNG for 20 years from Cheniere Marketing on a free-on-board basis for a purchase price indexed to the Henry Hub price, plus a fixed liquefaction fee. Deliveries will commence upon the start of commercial operations of the second train of the Sabine Pass Liquefaction Expansion Project in Louisiana and are subject to, among other things, a positive Final Investment Decision with respect to Train Eight.

09:50 EDT Gold Royalty to acquire royalty portfolio from SOQUEM for C$1M - Gold Royalty announced that it has entered into an agreement to acquire a portfolio of 22 royalties located in Quebec from SOQUEM, a subsidiary of Investissement Quebec, for C$1M in common shares of the company.

09:47 EDT CGI Inc. expands AI partnership with Google - CGI (GIB) announced the expansion of the company's partnership with Google (GOOGL) to drive innovation in the responsible use of artificial intelligence, or AI, technologies. This partnership will help clients accelerate their time-to-value from new generative AI use cases specific to their industries. As part of the agreement, CGI will leverage Google Cloud Platform to enhance the capabilities of its CGI PulseAI solution, a hyper-automation and decision engine platform that uses AI and machine learning models to deliver intelligent process automation.

09:47 EDT Pediatrix Medical falls -9.8% - Pediatrix Medical is down -9.8%, or -$1.10 to $10.11.

09:47 EDT Lemonade rises 23.0% - Lemonade is up 23.0%, or $2.52 to $13.53.

09:47 EDT Camping World rises 32.2% - Camping World is up 32.2%, or $5.56 to $22.84.

09:46 EDT Crescent Point Energy announces C$0.02 per share special cash dividend - Crescent Point Energy announced its board of directors has declared a quarterly cash base dividend and a special cash dividend in alignment with the company's return of capital framework. The quarterly cash base dividend of C$0.10 per share will be paid on January 2, 2024 for shareholders of record on December 15. Based on Crescent Point's Q3 financial results, a special cash dividend of C$0.02 per share will be paid on November 22, 2023 for shareholders of record on November 15.

09:44 EDT OmniLit Acquisition Corp trading resumes

09:43 EDT Co-Diagnostics awarded additional grant for tuberculosis test - Co-Diagnostics announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis test in development, designed to be run on the upcoming Co-Dx PCR platform. The amount awarded is $8.976 million. The Company's TB test, which Co-Dx has designed for afflicted markets worldwide highly burdened by the disease, will be applied towards regulatory and clinical validation activities, increasing manufacturing capacity, and additional platform software development. The grant will leverage the existing infrastructure and manufacturing capabilities of Co-Diagnostics' joint venture in India, CoSara Diagnostics. Those assets will be enhanced and expanded to help meet the anticipated demand for testing once the Co-Dx PCR platform, including the associated TB test, is available.

09:40 EDT Lindblad Expeditions trading resumes

09:40 EDT reAlpha Tech Corp trading resumes

09:39 EDT Bluebird Bio to present new and updated data from gene therapy programs at ASH - bluebird bio announced that new long-term efficacy, safety and health-related quality of life follow-up data from its lentiviral vector gene therapy programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular red blood cell transfusions will be presented at the 65th American Society of Hematology, or ASH, Annual Meeting and Exposition that will take place December 9-12. bluebird bio will present updated follow-up data for lovotibeglogene autotemcel, or lovo-cel, in patients from the HBG-206 Group C and HGB-210 studies with sickle cell disease followed for up to 60 months, demonstrating sustained hemoglobin AT87Q production and near-complete resolution of vaso-occlusive events and severe VOEs, as well as sustained improvements in HRQoL. lovo-cel treatment regimen largely reflects known side effects of hematopoietic stem cell collection and busulfan conditioning regimen and underlying sickle cell disease. "The bluebird bio data to be presented at ASH 2023 underscore the maturity of LVV gene therapies for hemoglobinopathies, with up to 9 years of follow-up data in transfusion-dependent beta-thalassemia and 5 years of follow-up in sickle cell disease. The robustness of this dataset is unparalleled, giving us continued confidence that the transformational impact these therapies may have for patients is sustained over time. We especially look forward to the first ever presentation of data from our long-term follow-up study of lovo-cel, the most deeply studied gene therapy in development for sickle cell disease," said Richard Colvin, M.D., Ph.D., Chief Medical Officer, bluebird bio.

09:35 EDT Criteo trading resumes

09:33 EDT Focus Financial appoints Eric Amar as CGO - Focus Financial Partners announced four new executive appointments for Managing Directors Travis Danysh, Pradeep Jayaraman, Sukanya Kuruganti, and Eric Amar. These appointments reflect Focus' strategic evolution as a private company towards a more cohesive organization that seeks a common purpose, higher levels of collaboration, and which operates with greater levels of efficiency for the benefit of its partner firms and the clients they serve. As a testament to this commitment, Focus introduces Managing Directors Eric Amar, Travis Danysh, Pradeep Jayaraman and Sukanya Kuruganti in their new roles: Eric Amar assumes the role of Chief Growth Officer, directing Focus's organic programs. His mandate focuses on leading sales and marketing initiatives to establish scalable institutionalized organic growth practices, as well as enhancing client outcomes through Focus Client Solutions and Portfolio Solutions, Focus's expanded wealth and asset management offerings. Travis Danysh is Head of Mergers & Acquisitions, overseeing the team responsible for driving all Company M&A strategy and execution, as well as providing support to Focus partner firms with their own individual M&A growth strategies. Pradeep Jayaraman and Sukanya Kuruganti become Co-Heads of Partnership and Business Development, with responsibility for Focus partner firms, including value-add to grow organically and through mergers and acquisitions. Jayaraman is responsible for Focus West, and Kuruganti is responsible for Focus East partnerships.

09:31 EDT Confluent trading halted, volatility trading pause

09:30 EDT Lindblad Expeditions trading halted, volatility trading pause

09:30 EDT United Bancorp trading halted, volatility trading pause

09:30 EDT reAlpha Tech Corp trading halted, volatility trading pause

09:29 EDT Mustang Bio to present MB-106 CD20-targeted CAR-T data - Mustang Bio announced that interim Phase 1/2 data from Mustang's multicenter clinical trial of MB-106, a CD20-targeted, autologous CAR-T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, have been selected for a poster presentation at the 65th American Society of Hematology Annual Meeting, taking place December 9-12, 2023 in San Diego. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center. The abstract posted today on the ASH Annual Meeting website reported on four patients who received MB-106 at dose level 1, 3.3106 cells/kg: two patients with follicular lymphoma who achieved complete response as demonstrated by both PET-CT and bone marrow biopsy, one patient with Waldenstrom macroglobulinemia who achieved a very good partial response and one patient with transfusion-dependent hairy cell leukemia variant who continued to have stable disease with decreased bone marrow disease and who achieved complete transfusion independence which is ongoing at 6 months. All patients displayed MB-106 expansion, with peak levels between 7-14 days post-infusion, and CAR-T cell persistence is ongoing at 6 months. From a safety perspective, 3 patients experienced Grade 1 cytokine release syndrome and no occurrences of immune effector cell-associated neurotoxicity syndrome were reported. Dose-limiting toxicities were monitored through day 28, and no DLTs were observed at DL1. Because of this favorable safety profile, MB-106 is infused in the outpatient setting if allowed by the institution, except for the first patient in each DL cohort, who is kept for overnight observation after MB-106 administration. All four patients were heavily pre-treated, with a median of 5.5 prior lines of treatment. The WM patient in particular had nine prior treatments, including autologous stem cell transplant, and a high disease burden, and the patient's VGPR was notable for complete metabolic response by PET-CT, morphologic clearance of lymphoma in bone marrow and resolution of the immunoglobulin M paraprotein. Other high-risk features were observed in each of the two FL patients: progression of disease within 24 months of first-line treatment in one patient and prior CD19-targeted CAR-T therapy in the other. Finally, the HCL-v patient received non-conforming material following FDA authorization.

09:27 EDT Mangoceuticals launches charitable initiative in support of Men's Health Month - Mangoceuticals will donate a percentage of proceeds generated through the sale of its branded merchandise to select men's health and wellness charities throughout the month of November. Throughout November, a month dedicated to raising awareness of men's health issues, MangoRx will donate 50 percent of all branded merchandise profits to select charitable organizations that focus on supporting education and awareness around subjects such as prostate cancer, testicular cancer, and men's suicide.

09:26 EDT Blink Charging launches EQ 200 charger in UK, Ireland - Blink Charging announced the launch of its advanced EQ 200 charger in the UK and Ireland. The EQ 200 is one of a new generation of vehicle-to-grid, bi-directional chargers designed to boost the development of an effective EV charging infrastructure and enable the switch from static EV charging to more dynamic and sustainable energy management as grid technology develops.

09:24 EDT Shattuck Labs to present data from Phase 1 A/B trial of SL-172154 - Shattuck Labs announced the presentation of topline data from the dose escalation portion of its Phase 1 A/B clinical trial of SL-172154 as monotherapy and in combination with azacitidine in primarily R/R AML and HR-MDS patients. These data will be featured in a poster presentation at the 65th ASH Annual Meeting, which is being held both virtually and in San Diego, CA from December 9-12, 2023. Key Takeaways: SL-172154 monotherapy response was observed in a heavily pretreated patient with R/R AML after just a single cycle of treatment, as well as early efficacy signals for SL-172154 in combination with AZA in previously untreated HR-MDS with TP53 mutant patients. SL-172154 was tolerable at 3mg/kg as a monotherapy and in combination with AZA. Data Overview: As of the abstract data cut-off date of May 25, 2023, 37 adult patients with R/R AML and HR-MDS had received SL-172154 as monotherapy or in combination with AZA in the parallel staggered dose-escalation portion of a Phase 1A/B clinical trial. Preliminary signs of anti-leukemic activity: Monotherapy response in a R/R AML patient and early signals of anti-leukemic activity in patients with R/R AML who received SL-172154 in combination with AZA were observed in a dose-dependent manner. SL-172154 monotherapy response was observed in a heavily pretreated R/R AML patient who subsequently proceeded to allogeneic hematopoietic cell transplantation. Anti-leukemic activity, in the form of blast count reductions, was observed in R/R AML patients in combination with AZA and one patient subsequently proceeded to allo-HCT. Out of four evaluable previously untreated HR-MDS with TP53m patients, there was one confirmed complete response, one marrow complete response, and two stable diseases. Two patients subsequently proceeded to allo-HCT. SL-172154 had an acceptable safety profile as monotherapy and in combination with AZA. Infusion-related reactions were the most common SL-172154-related treatment-emergent AEs and were reported in 13 patients as monotherapy and 8 patients in combination with AZA. Other TEAEs observed were increased AST, ALT and nausea in monotherapy cohorts, and nausea in combination cohorts. All events of increased AST/ALT were transient. SL-172154 in combination with AZA had an acceptable safety profile with one dose-limiting toxicity event at 6mg/kg of SL-172154. The dose of 3 mg/kg is being evaluated in the dose expansion. CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose. SL-172154 induced elevations in serum IL-12p40, IP-10, IL-8, IL-10, MIP3alpha, and MCP1 with greater response at 3 mg/kg compared to 1 mg/kg and similar response between 3 mg/kg and 6 mg/kg. In bone marrow, abundant staining of SL-172154 was observed, along with a dose-dependent increase in phagocytic cells within mature myeloid immune cell compartments. Reduction in leukemic blasts was associated with an increase in mature myeloid and phagocytic cell phenotypes.

09:23 EDT CalciMedica's Auxora shows efficacy in presentation - CalciMedica announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora in asparaginase-induced pancreatic toxicity at the 65th Annual American Society of Hematology Meeting & Exposition December 9-12 in San Diego. The data to be presented by the study sponsor highlights promising early results of the investigational use of Auxora in children with acute lymphoblastic leukemia experiencing asparaginase-associated pancreatitis. The presentation includes results from the first cohort consisting of nine patients from the CRSPA study. Treatment with Auxora compared to the historical matched control group reduced the average number of days patients spent in the hospital from 13.4 to 6.3 days. Three control patients needed intensive care unit care compared to one treated patient and average number of days in the ICU was reduced from 5 to 3 days. Additionally, no CRSPA patients required total parenteral nutrition vs. 68.8% in the historical matched control group. Based on the results from cohort 1 of CRSPA, a dose level 1 has been established as the recommended dose of Auxora for children with ALL experiencing AIPT.

09:22 EDT Eledon Pharmaceuticals reports updated data from Phase 1b trial of tegoprubart - Eledon Pharmaceuticals reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023. At the time of data submission, results from the 11 participants in the Phase 1b trial demonstrated that tegoprubart is generally safe and well-tolerated in patients undergoing kidney transplantation. There have been no cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection commonly seen with tacrolimus. One participant experienced a mild T cell mediated rejection on day 99. This patient was treated for the rejection and remains in the study. There were no cases of graft loss or death. Aggregate mean estimated glomerular filtration rate - a measure of kidney function - was above 70 mL/min/1.73m2 at all reported time points after day 90. Historical studies have reported average eGFRs generally in the low 50 mL/min/1.73m2 range during the first year after kidney transplant using standard of care. One participant has completed the study with an eGFR of 91 at one year and is now enrolled in a Phase 2 open-label extension study, which will evaluate the long-term safety, pharmacokinetics, and efficacy of tegoprubart in participants who have completed one year of treatment in either the ongoing Phase 1b or Phase 2 BESTOW study. The Phase 1b open-label study has enrolled 11 participants who underwent kidney transplantation in Canada, Australia, and the United Kingdom. Each participant received rabbit antithymocyte globulin (ATG) induction and a maintenance regimen consisting of tegoprubart, mycophenolate mofetil, and corticosteroids. The primary endpoint of the study is safety. Other endpoints include characterizing the pharmacokinetic profile of tegoprubart, the incidence of biopsy proven rejection, and eGFR. In September, Eledon announced that the first participant had been dosed in the Company's Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. The multicenter, two-arm, active comparator clinical study is enrolling approximately 120 participants undergoing kidney transplantation in the United States and other countries to evaluate the safety, pharmacokinetics, and efficacy of tegoprubart compared to the calcineurin inhibitor tacrolimus. The BESTOW trial's primary endpoint is designed to test the potential superiority of tegoprubart vs. tacrolimus in post kidney transplant kidney function at 12 months as measured by eGFR. The Company expects to complete enrollment at the end of 2024.

09:19 EDT Allogene Therapeutics announces poster presentation at ASH meeting - Allogene Therapeutics announced that it will have two poster presentations focused on the importance of lymphodepletion in allogeneic cell therapy at the 65th Annual Meeting of the American Society of Hematology, ASH, taking place December 9-12, 2023 in San Diego, CA. The first poster is a comprehensive safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory Large B Cell Lymphoma and follicular lymphoma to characterize the overall safety profile when ALLO-647 is added to standard lymphodepletion. The second poster showcases translational results from ALPHA2 generated through a collaboration with researchers from The University of Texas MD Anderson Cancer Center. This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.

09:18 EDT CISO Global enters license agreement with CRG Research - CISO Global has announced the signing of a licensing agreement to provide its entire suite of next generation intellectual property to CRG Research, LLC.

09:18 EDT Rennova Health opens opiate treatment facility - Rennova Health announced that its behavioral health services subsidiary, Myrtle Recovery Centers has opened a Nonresidential Office-Based Opiate Treatment Facility. The facility began accepting patients on November 1, 2023 and is located adjacent to Myrtle's alcohol and drug treatment facility in Oneida, Tennessee.

09:17 EDT Assure Holdings granted extension by Nasdaq to regain compliance - Assure Holdings received notice from the Staff of the Listing Qualifications Department of The Nasdaq Stock Market that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b). The Rule requires a minimum $2,500,000 stockholders' equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. As previously announced, on August 16, 2023, the Company received notice from the Staff that the Company no longer satisfies the $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market, or the alternatives to that requirement - a $35 million market value of listed securities or $500,000 in net income in the most recent fiscal year or two of the last three fiscal years. The Company was provided 45 calendar days, or until October 2, 2023 to submit a plan to the Staff to regain compliance with the Equity Requirement. On October 2, 2023, the Company submitted its plan of compliance to the Staff. On November 1, 2023, the Staff provided notice to the Company that the Staff had granted an extension until January 22, 2024 to complete certain key steps of the Company's compliance plan and, assuming those steps are complete on or before January 22, 2024, the Company must demonstrate compliance upon filing its periodic report for the quarter ended March 31, 2024. If the Company fails to evidence compliance upon filing its periodic report for the quarter ended March 31, 2024, with the SEC and Nasdaq, the Company may be subject to delisting. In the event the Company does not satisfy these terms, Staff will provide written notification that its securities will be delisted. At that time, the Company may appeal Staff's determination to a Hearings Panel. The Company's Common Stock continues to trade on the Nasdaq Capital Market under the symbol "IONM".

09:15 EDT LPL Financial: ViewPoint Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial LLC announced today that five financial advisors with ViewPoint Wealth Partners have joined LPL Financial's broker-dealer, RIA and custodial platforms. The team reported having served approximately $550 million in advisory, brokerage and retirement plan assets, and joins LPL from Ameriprise. Based in Independence, Ohio, the team was founded by advisors Paul LaBanc CFP, CRPC, AAMS, AWMA and Donald Grassi CRPC, AAMS, AWMA, who formed their initial partnership in 2001. They grew the practice by building relationships and gaining respect in the retirement space, always putting clients first. Over the years, like-minded advisors and staff joined the team, which now includes fellow advisors Michael Kozlowski CRPC, Brian Miller CFP, CRPC, APMA and Jennifer Bower CRPC, Director of Client Relations Theresa Guerini and two support staff members. Collectively, the advisors have more than 115 years of industry experience, with each financial professional bringing different strengths to the team.

09:13 EDT Autolus Therapeutics to present clinical data updates at ASH meeting - Autolus Therapeutics announces the online publication of four abstracts submitted to the American Society of Hematology, ASH, Annual Meeting, to be held December 9 to 12, 2023. Title: Obecabtagene Autoleucel for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia: Pooled Analysis of the Ongoing FELIX Phase Ib/II Study. Summary: In this session, pooled analysis of data from all patients treated to date in the FELIX study will be presented, with an extended follow up. Data continued to demonstrate high rates of CR/CRi and a favorable safety profile. Additionally, subgroup analysis data suggests better outcomes in patients with low leukemia burden at screening/lymphodepletion, with higher rates of deep MRD negative complete remission and no Gr greater than or equal to3 CRS and one Gr greater than or equal to3 ICANS. Title: Development of a Phase I Study Evaluating the Activity of Modular CAR T for Multiple Myeloma Targeting BCMA and CD19 for Improved Persistence. In the MCARTY study, we demonstrate dual CD19/BCMA targeting, alongside feasibility of clinical grade manufacture by double-transduction. Clinical responses were seen in 6 of 6 evaluable patients. Title: Long-Term Efficacy and Safety of Obecabtagene Autoleucel in Adult Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Data from the pooled analysis of r/r ALL patients treated with obe-cel in the ALLCAR19 and FELIX Ib studies demonstrate that after a median follow up of greater than3 years approximately 30% of patients remain in remission without subsequent transplant. In the CLL and NHL cohorts of the ALLCAR19 study and with greater than2 years follow up, the studies show durable responses and a low incidence of serious infections. In summary, obe-cel shows durable remissions in a range of B-cell malignancies with an excellent and consistent safety profile. Title: Delivery of Obecabtagene Autoleucel for the FELIX Pivotal Study Demonstrating Robust Cell Processing, Robust Release Testing, and Reliable Logistics, Together with Readiness for Sustainable Patient Care. The FELIX study successfully demonstrated the robust operability of obe-cel manufacturing, QC and logistics processes, meeting target V2C and V2D. All apheresis starting material was successfully processed despite the multitude of constraints posed by the COVID-19 pandemic. Further optimization and improvements made during the study increased reliability, consistency and precision of the manufacturing process, and supported the development of a new obe-cel manufacturing facility with greater production capacity that aims to achieve a greater than or equal to95% manufacturing success rate with less than or equal to15-day V2C times.

09:12 EDT Disc Medicine announces multiple presentations at ASH Meeting - Disc Medicine announced several key updates and that it will present data from multiple programs in its hematology portfolio at the upcoming 65th American Society of Hematology Annual Meeting and Exposition, which will be held in San Diego, CA on December 9-12, 2023. Key Program Updates: Bitopertin: Enrollment for phase 2 BEACON and AURORA studies of bitopertin in EPP is complete; BEACON has been expanded to enroll adolescents; Interim analyses of the BEACON trial demonstrated significant and consistent improvements in light tolerance across patients: Observed magnitude of effects were comparable to previously reported improvements in sunlight tolerance; An initial sub-group analysis indicated that greater suppression of protoporphyrin IX was associated with increased maximal weekly sunlight tolerance: greater than10 hours of improvement on average in patients with a mean maximal PPIX reduction greater than30% and greater than4 hours of improvement on average in patients with mean maximal PPIX reduction less than30%; Updated BEACON data from all adult patients and with longer duration of therapy will be presented as an oral presentation at ASH, including: Measures of PPIX, photosensitivity, QOL, safety and tolerability; Preliminary analysis of the precedented pivotal endpoint, cumulative time in light over 6 months on days without pain; Topline AURORA data is expected to be presented in early 2024. DISC-0974: Dose escalation is ongoing for both phase 1b/2 studies of DISC-0974 in MF and anemia, and non-dialysis dependent chronic kidney disease; Initial data from the phase 1b/2 study of DISC-0974 in patients with MF and anemia will be presented at ASH; Data from 10-20 patients in the dose-escalation phase; Safety and changes in hepcidin, iron, and hemoglobin levels; Data from the 28 mg dose cohort of the phase 1b/2 study in NDD-CKD patients with anemia will be presented as part of the management call; Bitopertin and DISC-0974 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide.

09:10 EDT Instacart, Geissler's Supermarkets announce partnership - Geissler's Supermarkets, a seven-store IGA retailer with locations in Connecticut and Massachusetts, and Instacart announced a new partnership to bring Caper Carts, Instacart's artificial intelligence-powered smart carts, to all seven Geissler's locations, replacing a majority of their traditional shopping carts over the coming months. Caper Carts use computer vision and AI to automatically identify items as they're placed in the cart, and Geissler's will deploy them to transform the traditional checkout experience, allowing customers to bag as they shop and pay from wherever they are in the store. Customers will be able to use their loyalty account on the carts, giving them access to personalized promotions and savings as they shop. Geissler's was recently named "Retailer of the Year" by the Connecticut Food Association.

09:09 EDT eBay launchs 'Canal Street Wear' shop in NYC - eBay announces the launch of "Canal Street Wear," a retail shop in NYC with an unrivaled selection of authentic streetwear and sneakers from top eBay sellers. Shoppers will have access to authentic items from the most popular and coveted brands, verified by eBay Authenticity Guarantee - the marketplace's authentication service that recently expanded to streetwear.

09:08 EDT Kymera Therapeutics to present data from Phase 1 trial of KT-333 - Kymera Therapeutics announced that new KT-333 Phase 1 data highlighting safety, pharmacokinetics, pharmacodynamics and clinical responses will be presented at the ASH 65th Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego, California. Results released in an ASH abstract today include data as of a July 10, 2023 cut-off. The poster presentation is expected to include additional data, including PK/PD, safety and results of disease response assessments from additional patients subsequent to the abstract cut-off date. In addition, preclinical data will be presented supporting the potential of STAT3 protein degraders as a therapeutic approach in venetoclax-resistant Acute Myeloid Leukemia. Highlights of the KT-333 Clinical Abstract: The abstract reported Phase 1 data from 21 patients enrolled through dose level 5; 12 were evaluable for disease assessment, including 1 with cutaneous T-cell lymphoma and 1 with peripheral T-cell lymphoma (PTCL) at DL2, and 10 with solid tumors at DL1-4. Highlights include: One partial response reported after two cycles in a CTCL patient at DL2, and stable disease reported after two cycles in three solid tumor patients treated at DL3 and DL4. PD data in blood available for DL1-4 demonstrated robust, dose-dependent, and sustained STAT3 degradation in peripheral blood mononuclear cells that, particularly at DL3 and beyond, were at levels associated with anti-tumor activity in preclinical models. No dose limiting toxicities or serious adverse events were reported; the most common adverse events were Grade 1/2 constipation, fatigue, nausea, and anemia. These data provide evidence of STAT3 targeted protein degradation in humans with associated STAT3 pathway inhibition, along with early signs of antitumor activity, highlighting the potential of heterobifunctional degraders for targeting previously undruggable transcription factors.

09:08 EDT LiqTech enters distribution agreement with Waterco in Australia and Asia Pacific - LiqTech has entered into an exclusive distribution agreement with Waterco for the distribution of LiqTech's Aqua Solution swimming pool water filtration systems covering Australia, New Zealand, Papua New Guinea, and the Pacific Islands. Waterco has worked with LiqTech successfully in the past 3 years to bring solutions to their joint customers.

09:06 EDT Adamas One announces initial delivery of lab-grown colorless diamonds - Adamas One announces the initial delivery of colorless diamonds. Adamas One's extensive internal R&D efforts lead to the successful creation of D, E and F diamonds, which are considered to be colorless as determined by gem grading labs such as GIA, IGI, and EGL.

09:06 EDT Allegiant Travel narrows 2023 system ASMs view to up 1.8% from 0%-3%

08:59 EDT Loop Industries to present Infinite Loop tech at groundbreaking ceremony - Loop Industries announced an updated schedule for the groundbreaking ceremony of the Ulsan ARC. The event is now scheduled to take place on November 15th, 2023. In addition, a press conference is planned to take place the day before the ceremony on November 14th, 2023, in Seoul, South Korea. Daniel Solomita, Loop's Founder and CEO, is scheduled to present the Infinite Loop technology at the event which is planned to be attended by top executives of the SK group, senior government officials, customers, media, environmental institutions, and academic experts. The Infinite Loop Ulsan facility, which Loop is planning with its strategic partner SK geo centric, is anticipated to begin construction by the end of 2023 and reach completion by the end of 2025.

08:57 EDT IntercontinentalExchange boosts dividend 11% to 42c per share - Intercontinental Exchange announced today a 42c per share dividend for the fourth quarter of 2023, which is up 11% from the 38c per share dividend paid in the fourth quarter of 2022. The cash dividend is payable on December 29 to stockholders of record as of December 14, 2023. The ex-dividend date is December 13.

08:55 EDT IntercontinentalExchange sees Q4 operating expenses 1.21B-$1.22B - ICE's fourth quarter 2023 GAAP operating expenses are expected to be in a range of $1.21 billion to $1.22 billion. Adjusted operating expenses(1) are expected to be in a range of $955 million to $965 million.

08:55 EDT Ford reports October U.S. sales down 5.3% to 149,938 vehicles - Ford reports total October U.S. sales decline 5.3% from last year to 149,938 vehicles, with Electric vehicle sales of 6,831 up 9.1%, Hybrid vehicle sales of 13,155 up 37.9% and Internal Combustion vehicle sales of 129,952 down 8.8%. Reference Link

08:52 EDT Camber Energy secures dismissal of class action lawsuit - Camber Energy announced the dismissal of the previously disclosed Class Action Complaint filed against the Company et al. titled Ronald E. Coggins v. Camber Energy et al. in the U.S. District Court for the Southern District of Texas, Houston Division, pursuant to which the Plaintiffs sought to recover damages alleged to have been suffered by them as a result of the defendants' alleged violations of federal securities laws. On September 22, 2023, the Court granted the Company and other defendants' motions to dismiss in full, and on October 25, 2023, the Court signed a joint stipulation submitted by the parties, dismissing the case with prejudice.

08:51 EDT Arqit Quantum, DETASAD announce strategic teaming agreement - Arqit Quantum and DETASAD, a provider of telecommunications and Technology Solutions in the Kingdom of Saudi Arabia, announced that Arqit's Sovereign Symmetric Key Agreement Platform will be launched in the Kingdom of Saudi Arabia by DETASAD this month. DETASAD, a market leader in data center and cloud services, cybersecurity and intelligence infrastructure solutions proudly announces expanding its cutting-edge partnership with Arqit, a global leader in quantum-safe cybersecurity. Together, the team is currently building a fully data-sovereign stack integrating Arqit's groundbreaking Symmetric Key Agreement solution, a technology that integrates seamlessly into existing networks to create trusted connections and secure communication links for any networked device, cloud machine or application. Secure against current and future forms of attack on encryption including from a quantum computer, the platform enhances security, resilience and the dynamic management of today's networks.

08:47 EDT Arteris IP, Semidynamics partner to accelerate AI RISC-V - Arteris announced a partnership to accelerate electronic product innovation for artificial intelligence, machine learning and high-performance computing applications. The partnership supports the interoperability between Semidynamics' Atrevido and Avispado 64-bit RISC-V processor IP cores and Arteris' Ncore cache coherent network-on-chip system IP. The combined solution delivers interoperability to speed up the development of AI/ML and HPC designs. "For markets like machine learning, key-value stores and recommendation systems, we optimize our customizable RISC-V processors and supporting technologies, such as Vector Units, Tensors Units and Gazzillion, to deal with the computing of highly sparse data, with long memory latencies, and high-bandwidth memory systems," said Roger Espasa, CEO of Semidynamics. "Efficient data transport within our cores and between chips and chiplets is vital for overall system performance. Partnering to pre-integrate with Arteris' Ncore cache coherent technology will result in accelerated project schedules for our mutual customers."

08:45 EDT Star Equity announces acquisition of Big Lake Lumber - Star Equity announced it has completed the acquisition of Big Lake Lumber, a Minneapolis-based building supply center and lumber yard, effective October 31, 2023. Big Lake will be integrated into Glenbrook Building Supply, one of the businesses in Star's Construction division. "We are excited to announce this important transaction for Star and Glenbrook," said Rick Coleman, Star's CEO. "This complementary bolt-on establishes Glenbrook as a regional player in the twin cities metro area and expands its client base. Furthermore, the accretive transaction immediately diversifies Glenbrook's revenue mix by adding more single-family residential business and presents opportunities for margin synergies going forward - both of which we expect to generate substantial value for Star shareholders." Following the acquisition of Big Lake, Star will remain composed of two divisions: Construction and Investments. Big Lake Lumber will be rebranded as a new location within Glenbrook. Star will continue to pursue its growth strategy as a diversified holding company through both organic growth and acquisitions.

08:43 EDT CME Group reached ADV of 25.2M contracts in October - CME Group reported its October 2023 market statistics, reaching an average daily volume of 25.2M contracts during the month, an increase of 11% over 2022 and the company's highest-ever October ADV on record. Reference Link

08:42 EDT BorgWarner secures contract with global OEM for high voltage coolant heater - BorgWarner has reached an agreement with a major global OEM to supply its 400V high voltage coolant heaters for the automaker's European light vehicle program. The anticipated start of production for the HVCH technology is in 2026. This business win marks the second HVCH contract secured with the global automaker over the course of two months, with the wins spanning different regions.

08:41 EDT Spetz announces convertible debenture, warrant offering - Spetz has completed an offering of secured convertible debentures and common share purchase warrants to arm's length parties for aggregate gross proceeds of $906,673. In connection with the offering of Debentures, the Company has issued 450,000 Warrants. Each Warrant entitles the holder thereof to subscribe for one common share in the capital of Spetz at an exercise price of $0.24 for a period of three (3) years from the date of issuance. The Debentures shall bear interest at a rate of 1% per month, calculated monthly in advance, and shall be payable, in cash, quarterly. Spetz reserves the right to repay the Debentures, without penalty, in whole or in part, prior to the Maturity Date, on 30 days prior written notice to the holders of the Debentures in advance of repayment or redemption. The principal amount of each Debenture shall be convertible, for no additional consideration, into Common Shares at the option of the holder at any time prior to the Maturity Date at a conversion price equal to $0.24 per Common Share. The proceeds from the issuance of the Convertible Debentures will be used for general working capital purposes.

08:41 EDT Kelly Services to sell European staffing business to Gi Group Holdings S.P.A. - Kelly announced that it has entered into a definitive agreement to sell its European staffing business to Gi Group Holdings S.P.A., one of the largest staffing companies in Europe, for cash consideration of up to EUR130M. The transaction is expected to close in the first quarter of 2024, subject to receipt of required regulatory approvals and other customary closing conditions. Under the terms of the agreement, Kelly will transfer its European staffing business within its International operating segment to Gi. Kelly provides staffing services to customers in 14 countries across Europe. The company will retain its managed service provider, recruitment process outsourcing, and functional service provider business with customers in the Europe, Middle East, and Africa region.

08:39 EDT PaxMedica has engaged Bourne Partners - PaxMedica has engaged Bourne Partners, a leading financial services firm specializing in the pharma, pharma services, and consumer health sectors. This marks an important step in PaxMedica's efforts to explore potential monetization of a Priority Review Voucher, PRV, prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness. The engagement with Bourne Partners underscores PaxMedica's commitment to optimizing its valuable assets to support the development of innovative healthcare solutions. Leveraging Bourne Partners' extensive experience and network within the healthcare sector, PaxMedica aims to enhance its initiatives in the field of neurologic disorders and expedite critical research and development efforts. "We are excited to engage Bourne Partners to explore the structures that could potentially allow the company to monetize the value of a potential PRV," stated Howard Weisman, Chairman and CEO of PaxMedica. "This represents our continued dedication to advancing healthcare solutions and underscores our commitment to driving meaningful change in the field of neurology." PaxMedica anticipates qualifying for the PRV program as their treatment targets a rare, fatal tropical disease caused by a parasite currently listed by the FDA as eligible for the program. However, it's important to note that PaxMedica has not been granted a PRV, and there is no guarantee that one will be awarded.

08:38 EDT Acer Therapeutics announces ISS, Glass Lewis recommended 'FOR' proposed merger - Acer Therapeutics announced that Institutional Shareholder Services, ISS, and Glass, Lewis & Co., Glass Lewis, recommended that Acer shareholders vote "FOR" the proposed merger with Zevra Therapeutics, Inc. and the related proposals in the Company's proxy statement and prospectus for the special meeting of its shareholders to be held on November 8, 2023 at 11:00 a.m. Eastern Time. ISS and Glass Lewis are widely recognized as the leading independent voting and corporate governance advisory firms. Their analysis and recommendations are relied on by many major institutional investment firms, mutual funds and fiduciaries throughout North America. In its report, ISS stated, among other things, that "The transaction warrants support in light of the reasonably thorough review of alternatives, the positive market reaction, the upside potential provided by the stock and CVR forms of consideration, and the downside risk of non-approval." Glass Lewis concluded that the transaction would allow Acer shareholders to participate in a larger and better capitalized pharmaceutical company, while also retaining significant upside potential through the CVR consideration, at a time when Acer appears to have few, if any, viable alternatives.

08:37 EDT Birkenstock progresses deleveraging program - Following its initial public offering on the New York Stock Exchange, Birkenstock Holding is moving forward with its deleveraging program and is utilizing the net proceeds from the IPO, together with cash on hand, to repay existing debt. The revered global zeitgeist and purpose brand today announced the early repayment of USD 450 million on its USD Term Loan B and EUR 100 million on its EUR Vendor Loan - both loans were solely issued to finance the acquisition of BIRKENSTOCK by L Catterton in April 2021, while the company is running a profitable and cash-rich business and pursues a very conservative financial policy as evidenced by the evolution of operating cash-flow. As a result of the prepayment, BIRKENSTOCK has reduced its total debt from approx. EUR 1,840 million to approx. EUR 1,314 million. The aggregate amount of the early loan repayments is significantly higher than envisaged in the IPO prospectus reflecting the Company's continued excellent operating results. The early loan repayments strengthen the Company's balance sheet while achieving additional financial flexibility. With a leverage ratio that is in line with industry benchmarks BIRKENSTOCK is well positioned to continue on its strong growth trajectory. Since entering into the new capital structure in April 2021, BIRKENSTOCK has reduced its leverage from above 6x to below 2.5x through repaying debt and growing EBITDA. BIRKENSTOCK plans to continue its deleveraging process and aims to achieve a leverage ratio of below 2x within the next 18 months. Long-term, the Company expects to achieve a leverage ratio of below 1x. On November 2, 2023, at the end of the current interest period, BIRKENSTOCK made an early partial repayment of USD 450 million on its USD Term Loan B, resulting in an outstanding balance of USD 331 million. Furthermore, on October 16, 2023, the Company completed an early partial repayment of EUR 100 million on the Vendor Loan, leaving an outstanding balance of approximately EUR 200 million. The EUR 200 million ABL revolving credit facility remains fully undrawn and therefore available in its entirety to BIRKENSTOCK. The early payments reflect the Company's strong liquidity position and underscore its strong financial performance, commitment to prudent capital management and ability and ambition to invest into key growth areas by unlocking white-space growth opportunities over the long-term.

08:34 EDT Imax, EVT expand partnership - EVT and IMAX announced an agreement for five new state-of-the-art IMAX with Laser systems across Australia and Germany. Under the deal, EVT will integrate a new IMAX screen experience in an Event Cinemas location in Sydney, as well as at four CineStar locations in Germany. The agreement comes on the heels of EVT's highly successful launch of IMAX Sydney, which in its first few weeks of operation, is already the highest grossing IMAX location worldwide outside the United States and United Kingdom. It also marks the single biggest deal for IMAX systems in Germany.

08:33 EDT enGene debuts as publicly traded genetics medicine company - Lumira Ventures portfolio company enGene Holdings has completed a business combination with a special purpose acquisition company and a concurrent oversubscribed private investment in public equity financing. As a result of this combination, enGene has become a publicly traded company whose shares are now listed on the Nasdaq market under the symbol "ENGN." Gross proceeds from this transaction totaled approximately CAD$191 million. With operations in Montreal and Boston, enGene is currently enrolling patients in a pivotal trial of its lead program EG-70 in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. EG-70 was developed using the company's proprietary Dually Derivatized Oligochitosan platform, which enables a carrier to penetrate mucosal tissue and deliver a wide range of sizes and types of cargo, including DNA and various forms of RNA, by turning mucosal cells into therapeutic production "factories" that generate proteins and RNAs for a desired local effect. "We are extremely proud of the progress enGene has made since our foundational investment in the company in 2015 via our Merck Lumira Biosciences Fund," stated Peter van der Velden, Managing General Partner of Lumira Ventures. "That fund focused on identifying and building transformative biotechnology companies in Quebec, and enGene is certainly fulfilling that promise. Our commitment to the company runs deep and we are pleased to have provided the continuity of capital that is so critical for success in our sector, via investments in enGene from multiple Lumira-managed funds, including most recently via Lumira Ventures Fund IV's participation in the PIPE transaction." "Lumira Ventures financial support and strategic guidance have been critical to enGene's ability to develop our therapeutic platform, build a world-class team, and complete this important transaction," said Jason Hanson, Chief Executive Officer of enGene. "We now look forward to advancing our shared mission to expand genetic medicine into the mainstream of clinical practice and address the high disease burden faced by patients in our areas of focus." Gerry Brunk, Managing Director of Lumira Ventures and enGene board member, added: "We extend our appreciation to the entire enGene management team and board in achieving this important milestone, as well as to our longtime enGene co-investors, Fonds de solidarite FTQ and Forbion. We also note the support of this transaction by other Lumira limited partners Northleaf Capital Partners, Investissement Quebec, and other new investors including BVF Partners, Omega Funds, Cowen Healthcare Investments, and Vivo Capital." Based on data from Pitchbook and the CVCA, we believe enGene's entry onto the Nasdaq exchange represents the first Canadian biotechnology company to debut in the public markets since 2020. We also believe that the company's oversubscribed PIPE is the largest equity financing for a private or public Canadian biotechnology company in 2023.

08:32 EDT Acurx says Phase 2 ibezapolstat trial met primary objective - Acurx Pharmaceuticals announced efficacy results from the Phase 2 clinical trial of ibezapolstat for the treatment of C. difficile Infection. The company previously announced that it decided to terminate the Phase 2b vancomycin-controlled trial segment early based on aggregate blinded data showing a high observed clinical cure rate with no emerging safety concerns. The company made this decision in consultation with its medical and scientific advisors based on the compelling clinical observation that the clinical cure rate for ibezapolstat was projected to be at least 90% pooled across the open-label Phase 2a and the blinded Phase 2b segments with no safety concerns noted. Other factors also influenced the decision, including the cost of maintaining clinical trial sites and the challenging enrollment environment in the U.S. due to the COVID-19 pandemic and its aftermath. The Phase 2b trial was originally designed to be a non-inferiority trial and later amended to include an interim efficacy analysis with review by an Independent Data Monitoring Committee. The decision to end the trial early based on blinded clinical observations obviated the need for an interim analysis, IDMC review, and NI assessment. The Company determined, in consultation with its clinical and statistical experts, that presenting clinical cure rates for the primary efficacy endpoint is the most appropriate representation for the clinical activity of ibezapolstat in treating CDI. The overall observed Clinical Cure rate in the combined Phase 2 trials in patients with CDI was 96%, based on 10 out of 10 patients in Phase 2a in the Modified Intent to Treat Population, plus 15 out of 16 patients in Phase 2b in the Per Protocol Population, who experienced Clinical Cure during treatment with ibezapolstat. Ibezapolstat was well-tolerated, with three patients each experiencing one mild adverse event assessed by the blinded investigator to be drug-related. All three events were gastrointestinal in nature and resolved without treatment. There were no drug-related treatment withdrawals or no drug-related serious adverse events, or other safety findings of concern. In the Phase 2b vancomycin control arm, 14 out of 14 patients experienced clinical cure. The Company is confident that based on the pooled Phase 2 ibezapolstat clinical cure rate of 96% and the historical vancomycin cure rate of approximately 81%, we will demonstrate non-inferiority of ibezapolstat to vancomycin in Phase 3 trials in accordance with the applicable FDA Guidance for Industry.

08:30 EDT Wearable Devices successfully delivers second batch of Mudra bands - Wearable Devices (WLDS) announced the completed shipment of the second manufacturing batch of the Mudra Band for Apple (AAPL) Watch. This second shipment becomes as the Company continues to fulfill preorders for this product. The Company plans to gradually ramp up production through the balance of 2023 and into 2024 to both fulfill preorder demand and support its go-to-market strategy for the holiday season and 2024. The Company now has thousands of Mudra Band units in advanced manufacturing and production phases. Asher Dahan, Chief Executive Officer of Wearable Devices, commented, "We're pleased to have completed shipment of the second manufacturing batch of the Mudra Band for Apple Watch to preorder customers. We've received positive initial feedback on the band, and our focus is on continuing to assure the highest production quality while we scale our manufacturing. With over 100 million Apple Watch devices sold to date, the addressable market for our product is immense and growing. We are actively engaging with multiple prospective retail distribution partners as part of our go-to-market strategy. We're seeing encouraging interest in the product from consumers and potential retail partners alike, and look forward to completing our preorder fulfillment, further scaling manufacturing and executing a strategic product roll out to capitalize on the market opportunity in front of us," Mr. Dahan concluded.

08:29 EDT Panbela announces publication of preclinical, clinical data of CPP-1X - Panbela Therapeutics announces the publication of preclinical and clinical data from studies of CPP-1X in recent onset type 1 diabetes, T1D. According to Sims et al, although therapy of T1D has improved, the morbidity, mortality and cost continue to impact the quality of life for those affected highlighting the need for safe and effective therapies that address the underlying pathology. Data published in the journal Cell Reports Medicine investigated the mechanism of polyamines and polyamine inhibition by CPP-1X on beta cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models. Results showed that DFMO treatment may preserve beta cell function, reflected by C-peptide levels in patients with T1D through the modulation of urinary polyamines, in particular putrescine. From the Phase 1 dose range finding study of CPP-1X in patients with recent onset T1D, CPP-1X was well tolerated and a dose dependent inhibition of ODC was observed. An exploratory secondary analysis showed that at the two highest dose levels, treatment with CPP-1X stabilized C-peptide areas under the curve compared to placebo. When assessing immune cell populations, there were no differences between the placebo and CPP-1X patients. Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve beta cell function and/or survival in recent onset T1D. "By investigating beta cell-specific deletion of ornithine decarboxylase in preclinical models, our collaborators were able to demonstrate the protection against toxin-induced diabetes which suggests a role for polyamine dysregulation in T1D." said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "This observation was extended to the clinical setting where results from the multi-site randomized, placebo-controlled Phase I trial in patients with recent onset T1D showed that inhibition of ODC by CPP-1X may improve beta cell function."

08:27 EDT vTv Therapeutics appoints Strack as CMO - vTv Therapeutics announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, CMO, effective immediately. Dr. Strack most recently served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies.

08:27 EDT Trevi Therapeutics initiates Phase 2a RIVER clinical trial of Haduvio - Trevi Therapeutics announced the initiation of its Phase 2a RIVER clinical trial evaluating Haduvio in RCC patients. RCC affects up to 10% of adults worldwide and is defined by a cough that lasts greater than 8 weeks and does not respond to therapy for an underlying condition. Topline data from the RIVER trial is expected in the second half of 2024.

08:26 EDT Vaxart doses first subject in Phase 1 trial of norovirus vaccine candidate - Vaxart has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

08:25 EDT Amgen presents new data on KRYSTEXXA - Amgen announced new data for KRYSTEXXA showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment - uncontrolled gout - both with and without chronic kidney disease. The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia. In the MIRROR randomized controlled trial, 152 adults were randomized 2:1 to receive KRYSTEXXA with methotrexate or KRYSTEXXA with placebo for 52 weeks. Treatment groups had similar blood pressure prior to treatment. The decrease in systolic blood pressure during treatment was greater at Week 24 of treatment and more sustained over the full 52-week treatment period in patients receiving KRYSTEXXA with methotrexate than in those receiving KRYSTEXXA with placebo. Compared to those with pre-treatment CKD, patients without pre-treatment CKD had a more pronounced decrease in blood pressure after Week 24 of treatment, with differences persisting through Week 52 of treatment.

08:23 EDT I-Mab granted FDA Breakthrough Therapy Designation for felzartamab - I-Mab announced that the U.S. FDA has granted Breakthrough Therapy Designation for felzartamab, an investigational CD38 antibody, for the treatment of primary membranous nephropathy.

08:22 EDT Kimbell Royalty Partners raises Q4 production view to 22.5-24.3 Mboe/d

08:22 EDT Regulus: First patient dosed in third cohort of Phase 1b MAD study of RGSL8429 - Regulus Therapeutics announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. "After announcing the completed safety review of available data and the advancement to cohort three last month, we are excited to now be dosing our first patient in the third cohort," said Jay Hagan, CEO of Regulus Therapeutics. "Our Phase 1b MAD clinical trial remains on track, and we look forward to sharing topline data from the second cohort of the study in the first quarter of 2024."

08:21 EDT Gentherm initiates $60M accelerated share repurchase - Gentherm (THRM) announced that it has entered into an accelerated share repurchase agreement, ASR, with Bank of America (BAC), to repurchase an aggregate of $60 million of Gentherm's common shares. The agreement was entered pursuant to the Company's previously announced stock repurchase program. The Board of Directors authorized an extension of the stock repurchase program through June 30, 2024, which had approximately $97 million remaining as of October 31, 2023. The Company will initially receive approximately 1.22M common shares. The final number of shares to be repurchased will be based on the volume-weighted average price of Gentherm's common shares during the term of the transaction, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR. The final settlement of the transactions under the ASR is expected to occur no later than the second quarter of 2024. "I am pleased to announce our $60 million ASR, which reflects the strength of our balance sheet, cash flow generation and ample liquidity, as well as management and our Board's continued confidence in our ability over time to grow faster than automotive production while improving profitability," said Matteo Anversa, Executive Vice President of Finance, Chief Financial Officer and Treasurer. "Returning capital to our shareholders through stock repurchase programs while simultaneously investing in our strategic growth drivers, is consistent with our capital allocation strategy and commitment to increasing shareholder value."

08:20 EDT Bionano Genomics announces OGM was included in a medical school textbook - Bionano Genomics announced that optical genome mapping, OGM, was included for the first time in Thompson and Thompson Genetics and Genomics in Medicine, 9th edition, a textbook regularly used for medical students, genetic counseling students, students in laboratory medicine, and more advanced trainees pursuing American Board of Medical Genetics and Genomics, ABMGG, residency and laboratory fellowships in clinical biochemical genetics, laboratory genetics and genomics, and clinical molecular genetics. "Inclusion in this book is a significant milestone for OGM and for people in the various fields of genome analysis who are looking for ways to move the community forward. We were pleased to see the authors note OGM's ability to detect clinically relevant SVs that other methods, including LRS, miss, while citing OGM's potential lower cost and greater accuracy, particularly as the SVs detected by OGM in research may ultimately lead to improved diagnosis and detection of genetic disorders," added Erik Holmlin, PhD, president and chief executive officer of Bionano.

08:19 EDT Brainsway announces CMS published first coverage recommendation for TMS - BrainsWay announced today that the Clinical TMS Society, CTMSS, an influential medical society dedicated to supporting the clinical practice, research, and access to transcranial magnetic stimulation, TMS, has published the first coverage recommendations for smoking addiction treatment using TMS. BrainsWay Deep TMS is the only TMS technology to have received FDA clearance for the treatment of smoking addiction. "We are encouraged by the ongoing efforts of the Clinical TMS Society to drive favorable coverage for TMS around the world," said Aron Tendler, MD, Chief Medical Officer of BrainsWay. "Nicotine use continues to be the leading cause of preventable death across the globe, and based our data, Deep TMS can be a beneficial solution for those looking to quit without prior success."

08:18 EDT American Oncology Network launches new cancer foundation - American Oncology Network announced the launch of its cancer foundation, the American Oncology Cares Foundation. The Foundation will raise funds to provide essential non-medical financial assistance for adult cancer patients.

08:16 EDT Rhythm receives positive CADTH reimbursement recommendation for IMCIVREE - Rhythm Pharmaceuticals announced that the Canadian Agency for Drugs and Technologies in Health, CADTH, has recommended that IMCIVREE be reimbursed by CADTH-participating public drug plans, with conditions, for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome. "This positive CADTH recommendation will be welcome news for the patients and families living with hyperphagia, which is a pathological and insatiable hunger, and the severe obesity that is often associated with BBS," said Prof. Andrea M. Haqq, M.D., Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta. "This important recommendation further recognizes the unmet needs of people with BBS who otherwise have no targeted precision treatment for weight management."

08:16 EDT Alpha Metallurgical sees 2024 CapEx $210M-$240M - Expects to ship between 15.5 million and 16.5 million metallurgical tons in 2024, as well as incidental thermal coal of between 0.9 million and 1.3 million tons, bringing total expected 2024 shipments to a range of 16.4 million to 17.8 million tons.

08:15 EDT Bieases selects authID to secure digital wallet - authID and Bieases announced that they will launch authID's biometric authentication platform to stop identity fraud and account takeover with automated digital customer onboarding and passwordless authentication. Bieases delivers international financial services and payments in top global markets including the United States, United Kingdom, and the European Union. Through its digital wallet, Bieases supports a robust network between banks, merchants, and their customers, helping merchants collect money both online and offline-domestically and internationally, and offering individual customers the most attractive international money transfer service.

08:13 EDT Silk Road Medical names McKhann as CEO - Silk Road Medical announced that Chas McKhann has been appointed Chief Executive Officer, CEO, effective immediately. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, McKhann served as President and CEO of Apollo Endosurgery.

08:13 EDT Marriott sees higher RevPAR growth internationally vs. U.S. in Q4

08:12 EDT ReWalk Robotics announces CMS coverage for ReWalk Personal Exoskeleton - ReWalk Robotics announced its appreciation to the Centers for Medicare & Medicaid Services, CMS, for finalizing the Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780 which solidifies the inclusion of exoskeletons in the Medicare brace benefit category. The final rule was released by CMS on November 1, 2023 and will go into effect beginning on January 1, 2024. In the final rule, CMS reiterates that including exoskeletons within the existing brace category will "expedite coverage and payment for newer technology and powered devices, potentially providing faster access to these new healthcare technologies for Medicare beneficiaries," and will "particularly help those with disabilities associated with muscular and/or neural conditions." "Finalization of this rule by CMS is a major milestone in our efforts to expand access to this life-changing technology for the substantial proportion of the spinal cord injury community with Medicare coverage," said Larry Jasinski, CEO of ReWalk Robotics. "The vision at ReWalk has always been to enable broad access to walking, climbing curbs or stairs, and standing during eye-to-eye conversations in everyday life for individuals living with spinal cord injury. This technology has tremendous impacts for users at both a physical and psychological level. The decision by CMS to include personal exoskeletons within an existing benefit category in order to expedite Medicare coverage and payment is an important validation of the positive impact of exoskeletons, and a message that innovation matters in Medicare policy decisions."

08:11 EDT Worksport prepares for alpha release of COR battery system - Worksport is preparing for an alpha release of its highly anticipated COR battery system. In anticipation of the system's alpha release, the Company is streamlining its supply chain, marked by the strategic forging of partnership agreements with esteemed global suppliers. The Company expects this initial release of its COR battery system to serve as a preliminary user iteration prior to its anticipated mass-market release in North America, with future intentions of releasing the system in other key global markets. This invaluable phase aims to harness the feedback from a select group of test users to allow the Company to finetune the COR system, ensuring optimal performance, bug-free operation, and a seamless user experience. Worksport will provide a definitive alpha release date upon finalizing all requisite elements. In response to the increasing demand, Worksport is working hard to expand its production capabilities. Additionally, the Company's subsidiary, Terravis Energy, unveiled its plans this week to increase research and development for its groundbreaking heat pump, reflecting its confidence in the product's expansive market potential.

08:11 EDT Enphase Energy launches new IQ8 microinverters in Austria - Enphase Energy announced that it has started shipping IQ8 Microinverters, with peak output AC power of 384 W, in Austria to support newer, high-powered solar modules. This announcement follows the launch of the Enphase SolargrafSM platform in Austria. IQ8 Microinverters are designed to maximize energy production and can manage a continuous DC current of 14 amperes, supporting higher powered solar modules through increased energy harvesting. "At Enphase, we provide homeowners with industry-leading innovative solar energy systems," said Aaron Gordon, vice president and general manager of the microinverter business unit at Enphase Energy. "We're pleased to expand our line of products in Austria, enabling our installer partners to provide these systems capable of supporting the most powerful solar modules on the market."

08:10 EDT Accenture acquires Innotec Security, terms not disclosed - Accenture has acquired Innotec Security, a privately held company specializing in cybersecurity-as-a-service, cyber resilience and cyber risk management, expanding its capabilities and footprint in Spain. Innotec Security was previously owned by parent company Entelgy Group. Financial terms were not disclosed.

08:09 EDT Outlook Therapeutics provides update on Type A meetings with FDA - Outlook Therapeutics announced that it has completed the requested Type A Meetings with the U.S. Food and Drug Administration, FDA, to discuss the Complete Response Letter, CRL, dated August 29, 2023 regarding the Biologics License Application, BLA, for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. The FDA informed Outlook Therapeutics that an additional adequate and well-controlled clinical trial would be required for the approval of ONS-5010 for the treatment of wet AMD. During the meetings, Outlook Therapeutics reached an agreement in principle with the FDA on a clinical trial design that would most likely allow for the resubmission of the ONS-5010 BLA as early as the end of calendar year 2024, and subsequent approval around mid-2025, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trial. The FDA and Outlook Therapeutics also agreed on the approaches needed to resolve the CMC comments in the CRL and Outlook Therapeutics believes these efforts should be sufficient to support approval.

08:08 EDT Marriott sees net rooms growth 'squarely' in MSD range for next few years

08:04 EDT Criteo sees 2023 adjusted EBITDA margin 27%-28% of Contribution ex-TAC - Sees 2023 +9% to +10% growth in Contribution ex-TAC at constant currency, including the contribution from our Iponweb acquisition.

08:03 EDT Twin Disc board reinstates quarterly dividend of 4c per share - Twin Disc announced that the Board of Directors reinstated a regular quarterly cash dividend of $0.04 per share payable on December 1, 2023, to shareholders of record at the close of business on November 17, 2023. This resumption of Twin Disc's quarterly dividend following the suspension of the program in February 2016 reflects the Company's ongoing progress towards achieving its medium-term financial targets.

08:00 EDT Eskay Mining reports assay results from diamond drill, exploration campaign - Eskay Mining has received very encouraging assay results from its 2023 diamond drill and exploration campaign at its 100% controlled Consolidated Eskay Gold Project in the Golden Triangle of British Columbia. Precious metal-rich volcanogenic massive sulfide deposits are the focus of Eskay's exploration. Cumberland VMS Discovery: Nine short diamond core holes were completed at the Cumberland Showing in 2023, several of which encountered very promising precious and base metal-rich stockwork and massive mineralization. Notable results include: 3.02 gpt Au, 68.66 gpt Ag, 0.24% Cu, 0.73% Pb and 4.86% Zn over 15.00m including 8.48 gpt Au, 103.27 gpt Ag, 0.23% Cu, 1.08% Pb and 4.16% Zn over 3.41m in hole CBL23-28. 1.21 gpt Au, 29.22 gpt Ag, 0.12% Cu, 0.32% Pb and 2.94% Zn over 22.52m including 3.45 gpt Au, 108.21 gpt Ag, 0.65% Cu, 0.54% Pb and 19.40% Zn over 1.75m in hole CBL23-29. 0.68 gpt Au, 15.72 gpt Ag, 0.07% Cu, 0.27% Pb and 0.90% Zn over 45.67m in hole CBL23-30. 0.95 gpt Au, 29.04 gpt Ag, 0.07% Cu, 0.29% Pb and 1.31% Zn over 61.23m including 1.57 gpt Au, 58.80 gpt Ag, 0.16% Cu, 0.60% Pb and 3.13% Zn over 20.08m in hole CBL23-31. Cumberland lies approximately 6km due south of the TV deposit and is similarly situated along the east side of the Eskay anticline. Eskay's geologic team thinks this discovery opens up considerable exploration potential in areas between Cumberland and the TV-Jeff VMS complex. It is notable that mineralization at Cumberland displays very high base metals, an indicator of high formational fluid temperatures, a potential sign that this area lies in proximity to a major feeder vent or vents. Based upon data from this limited first phase drill program, the Cumberland VMS deposit is interpreted to be tabular with a N-S orientation and a near vertical dip, perhaps slightly overturned. It remains open along strike and at depth. A review of historic soil data from areas up to 1.5 km south of Cumberland indicates a broad area of strongly anomalous geochemistry, especially elevated silver values, confirming a likely extension of mineralization in this direction. Eskay's geologic team observed significant outcropping sulfide mineralization while conducting traverses in this region south of Cumberland. While prospecting late in the season, a notable area of outcropping sulfide mineralization was observed approximately 2.5 km to the northeast of Cumberland and is potentially part of the same VMS system. This area has been named Mahogany Ridge. Historic rock chip sample data from the broader Cumberland trend includes samples grading 25.0, and 27.9 gpt Au. Given the strong drill and rock chip sample results from the Cumberland-Mahogany Ridge area, Eskay Mining views this discovery as a high priority exploration target. Compelling evidence is emerging that the corridor starting at TV-Jeff in the north through Mahogany Ridge and Cumberland and continuing a further 1.5km south of Cumberland is highly prospective for further precious metal-rich VMS discoveries. Eskay Mining thinks this corridor requires urgent follow up work including drilling in 2024.

07:54 EDT Stack Capital reports book value per share of C$11.30 as of Sept. 30 - The Company's cash position as at September 30, 2023, was $25.8 million or $2.87 per share. "The continued growth across our portfolio companies is very encouraging," said Jeff Parks, CEO of Stack Capital. "The management teams of our underlying businesses have demonstrated the ability to not only weather the current economic environment but expand in the face of higher interest rates and inflationary pressures. As 2024 approaches, we're optimistic that this positive momentum can continue, which bodes well for potential future liquidity events."

07:51 EDT Rio Tinto, Midland provide assay results on Galinee project - Midland Exploration is pleased to provide new assay results and an update on completed and upcoming work following the identification of a series of spodumene-bearing pegmatite dykes on the Galinee project, approximately 8 kilometres east of the Adina lithium deposit held by Winsome Resources. The Galinee project is currently wholly owned by Midland and is subject to an option agreement signed with RTEC in June 2023. Field crews began working on Galinee following the complete lift of access restrictions in the James Bay region as a result of forest fires in the summer of 2023. The field program, which began near the end of August and lasted until October 12th, also included work on other projects under the same option agreement such as Corvette, Chisaayuu and Mythril East. Highlights: Spodumene-bearing pegmatite dykes identified over at least 600 metres strike length at Iceberg Showing with high-grade grab samples grading up to 7.2 % Li2O; New additional spodumene-bearing outcrops found 500 metres south and 900 metres southwest from Iceberg; LiDAR survey completed on Galinee, Chisaayuu, Corvette and Mythril East; High resolution MAG-RAD survey completed on Galinee; Drilling planning in progress on Galinee. Assay results have been received for the 26 samples collected at the Iceberg lithium discovery. High-grade grab samples returned up to 7.2 % Li2O, including 6 samples grading between 5.0 % Li2O and 7.2 % Li2O, 6 samples grading between 3.0 % Li2O and 5.0 % Li2O, and 3 other samples grading between 1 % Li2O and 3 % Li2O. The other samples returned anomalous lithium values below 1% Li2O. The Iceberg discovery was identified on several outcrops by field crews after a few days of prospecting. A combination of ultraviolet lamp and a LIBS analyzer were used to confidently identify spodumene, including some crystals reaching up to 60 centimetres in length. The Iceberg discovery consists of a series of spodumene exposures outcrop, now over a 600m east-west strike intermixed with amphibolite and granodiorite. Testing subtle local relief features in areas covered with vegetation and soil resulted in locating two new coarse spodumene-bearing pegmatite outcrops, located 500 and 900 metres south and southwest from the Iceberg showing. Assays are pending. The Galinee project is located approximately 4 kilometres due east of the Adina showing held by Winsome. This showing is located at the contact between amphibolites of the Trieste Formation to the south and felsic intrusives to the north. This contact is marked by a major structure that likely controlled the emplacement of pegmatites at the Adina showing. This new discovery, on Galinee, of spodumene-bearing pegmatite dykes was made along the same highly favourable contact zone, which is present on the property over more than 7 kilometres and which has never been explored for lithium in the past. This first exploration program included prospecting, geological mapping as well as a high-resolution LiDAR survey. Following the discovery, a high-resolution airborne magnetic and radiometric survey was completed. The LiDAR, imagery, magnetic and radiometric data will hopefully guide future work to expand the footprint of spodumene outcrops on Galinee. A maiden drilling campaign is currently being planned on Galinee. Initial exploration work on Chisaayuu, Corvette and Mythril East blocks was successful in identifying several pegmatites. No lithium phases were observed so far, but geochemistry of these pegmatites is underway to determine their full potential and for further vectoring.

07:50 EDT Repligen announced the commercial launch of TangenX SC - Repligen announced the commercial launch of TangenX SC, the industry's first holder-free, self-contained Tangential Flow Filtration, TFF, device. The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal, including antibody drug conjugates, viral vectors, nucleic acids and lipid nanoparticles, and can also be applied to monoclonal antibody, and recombinant protein production. Christine Gebski, Senior Vice President, Filtration and Chromatography at Repligen, said, "TangenX SC pushes the boundaries of TFF innovation, offering clear advantages to virtually any user of flat sheet TFF. The holder-free TangenX SC device simplifies and streamlines downstream flat sheet UF/DF processes like never before. Users can trust that the quality and consistency of their TFF processes remain uncompromised while enjoying the benefits of this innovative technology."

07:49 EDT Jeffs' Brands announces expected implementation of 1-for-7 reverse share split - Jeffs' Brands announced that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-7, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on November 3, 2023, under the Company's existing trading symbol "JFBR". The trading symbol "JFBRW" and CUSIP number for the Company's public warrants will remain unchanged following the reverse share split. The reverse share split was approved by the Company's shareholders at the Company's Annual Meeting of Shareholders held on September 5, 2023 to be effected in the board of director's discretion within approved parameters.

07:49 EDT Upwork launches Upwork Research Institute - Upwork launched The Upwork Research Institute to further the company's commitment to studying fundamental shifts in workforce dynamics, and provide business leaders with the insights and tools they need to navigate and prepare for the workforce of tomorrow. The Research Institute will help drive work transformation for organizations in two ways: Global survey research and original whitepapers: In collaboration with leading experts, academics, research firms and prominent Future of Work organizations, the Research Institute will conduct ongoing global survey research to understand attitudes and behaviors of executives across various industries and regions to create blueprints for companies striving to redesign work. Proprietary Upwork platform data: The Research Institute will analyze proprietary platform data on Upwork to uncover hiring behaviors across emerging skills, like generative AI; evolving customer habits; the growing supply of independent talent and the impact on market dynamics; and more.

07:47 EDT Avante Corp joins Global Shield Network - Avante Corp accepts an invitation to join the Global Shield Network, a law enforcement & intelligence network immersed in public/private sector partnerships designed to prevent crime, terrorism and improve public safety. After the safe and successfully evacuation of its clients from the conflict zone in Israel, Avante was recognized for its world-class security and crisis management services with an invitation to join the Global Shield Network. This collaboration marks a significant milestone for Avante, reinforcing its commitment to ensuring the safety and security of its clients both locally and internationally. Through this strategic alliance, Avante gains invaluable access to a wealth of up-to-the-minute information on major security incidents occurring around the world. This partnership empowers Avante to stay ahead of emerging threats and trends, enabling the Company to provide even more robust security solutions to its clients.

07:46 EDT Lifeist Wellness' Mikra completes formulation of mental health product - Lifeist Wellness announced that its U.S. biosciences subsidiary Mikra Cellular Sciences has completed the formulation and commenced production of a new and innovative supplement aimed at supporting the widespread modern struggle with anxiety. Serenity is a natural supplement containing a precise GCMS-verified dose of extract of lavender oil, formulated based on extensive studies including randomized, double-blind trials, with the results published in peer-reviewed clinical research.Serenity has been formulated based on lavender, a natural botanical extract, aligning with Mikra's core commitment to enhancing lives through natural ingredients, the power of science, and a focus on cellular health. Lavender oil extract has undergone thorough evaluation in randomized, double-blind clinical trials, where it demonstrated notable effectiveness even surpassing that of paroxetine, a leading SSRI recommended for managing generalized anxiety disorder5. This study's findings indicated that lavender oil extract is both efficacious and well-tolerated in patients with generalized anxiety disorder, enabling termination after a 10-week treatment at the full therapeutic dose without down-titration and without inducing withdrawal symptoms.

07:44 EDT Axsome announces it will help raise awareness of Alzheimer's disease - Axsome Therapeutics announced it is joining advocacy organizations around the world to help raise awareness of Alzheimer's disease and to stand in solidarity with all those affected by this condition and their families during Alzheimer's Disease Awareness Month. November marks Alzheimer's Disease Awareness Month, an important time to know the facts about this illness that affects millions.

07:41 EDT Yum China expands share repurchase authorization by $1B - Yum China reported that its Board of Directors has increased the company's share repurchase authorization by $1B to an aggregate of $3.4B. From 2017 to November 1, 2023, the company repurchased approximately 36M shares of common stock for $1.6B. This increase brings the total remaining authorization to approximately $1.8B.

07:40 EDT Dentsply Sirona announces appointment of Gladden as new board member - DENTSPLY SIRONA announced that Brian Gladden has been appointed to its Board of Directors, effective January 1, 2024, to fill the vacancy from Harry Jansen Kraemer, Jr.'s retirement on December 31, 2023. Gladden is currently the Chief Administrative and Chief Financial Officer of Zelis Healthcare.

07:39 EDT Applied UV secures new patent approval from USPTO - Applied UV announced the recent approval of patent US 11,788,265 B2 for its "INTERCHANGEABLE DRAIN DISINFECTING DEVICE." This patent underscores the Company's commitment to innovation and advancing solutions for healthier and safer environments. New Patent Approval - Interchangeable Drain Disinfecting Device: The Company's patent for this innovative device optimizes UV source irradiation to effectively disinfect drain systems, contributing to enhanced hygiene and safety. Fighter Flex LED Technology Patent Submission: In addition to this achievement, the Company has submitted a new patent to the United States Patent and Trademark Office for its Fighter Flex LED technology. Deepening the HVAC Product Roadmap: The Fighter FleM) LED technology deepens product roadmap in the HVAC space, offering advanced capabilities that enhance indoor air quality and energy efficiency. Testing and Partnerships:The Fighter Flex LED, alongside the Puro Protect, is currently undergoing stringent testing by the Federal Government as part of the GSA Green Proving Grounds Program. Current Testing at Mt Sinai University Hospital, NYC: Applied UV's Interchangeable Drain Disinfecting Device is currently undergoing rigorous testing at the esteemed Mt Sinai Hospital System in New York City.

07:38 EDT Starbucks sees FY24 global comp sales up 5%-7% vs. prior 7%-9% view

07:34 EDT MGP Ingredients CEO David Colo to retire, David Bratcher to succeed - MGP Ingredients announced that David Colo will retire from his role as CEO and President of MGP, effective December 31, 2023. The Board of Directors has elected David Bratcher, MGP's COO and President of Branded Spirits, as its next Chief Executive Officer and President, effective January 1, 2024. Mr. Colo will remain with MGP through April 2024, serving in an advisory role to facilitate a smooth transition. Colo will also resign from the Board of Directors effective December 31, 2023, and the Board has nominated Mr. Bratcher for election as a Class B director effective January 1, 2024, subject to preferred stockholder approval. Colo and Bratcher have worked closely together for more than two years since the successful merger and integration of MGP with branded spirits company Luxco, Inc. Since becoming the CEO and President of MGP in May 2020, Colo has led the Company through consistent growth and record results, while also establishing a strong foundation for future sustainable growth. Bratcher's appointment is a reflection of the Company's deliberate succession planning.

07:30 EDT Cara Therapeutics announces up to $40M financing agreement with HCRx - Cara Therapeutics announced it has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty, HCRs. Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral difelikefalin pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and notalgia paresthetica. Under the terms of the agreement, Cara will receive an initial payment of $17.5 million, less certain expenses. Cara will receive an additional payment of $20.0 million upon Kapruvia receiving a certain minimum price in Germany, which is expected to occur this quarter. In addition, if KORSUVA achieves certain specified 2024 performance levels in Japan, Cara will receive a $2.5 million milestone payment. In exchange, HCRx will receive all royalties due to Cara from KORSUVA injection / Kapruvia ex-U.S. license agreements with CSL Vifor and Maruishi Pharmaceutical Co., Ltd. The arrangement with HCRx specifically excludes KORSUVA injection in the U.S. and all of Cara's oral difelikefalin internal development programs.

07:28 EDT Alta Equipment Group acquires Ault Industries - Alta Equipment Group announced that it has acquired Ault Industries. Strategic and Financial Highlights: The acquisition expands Alta's Construction Equipment segment into Canada's two largest markets. As part of the acquisition, Alta assumes Ault's exclusive dealer agreement with McCloskey, a best-in-class product in the crushing and screening category. Given Ault's leading market position and strong brand relationships, the Company expects the acquisition to be accretive to the Company's EBITDA to cash flow conversion and earnings per share ratios. Additional Transaction Details: Total purchase price of $36.0 million, consisting of $23.2 million cash at close, a $2.2 million seller note, and $10.6 million worth of Alta's common stock, which will be issued at $13 per share, equating to 818,473 shares vesting annually over a five-year period. The purchase price is subject to post-closing working capital adjustments. Ault's brand name, employees, and management team will remain in place post-close. Including Ault, since the Company's initial public offering in 2020, Alta has completed 16 acquisitions which have contributed $537 million in revenue, and $66 million in Adjusted EBITDA.

07:27 EDT Climb Global expands cybersecurity offerings in North America - Climb Channel Solutions, a wholly owned subsidiary of Climb Global Solutions, has announced the launch of a new partnership with a leading provider of cybersecurity solutions, FireMon in North America. This collaboration brings together FireMon's cutting-edge cybersecurity expertise and Climb Channel Solutions' extensive network of technology providers across the United States and Canada. Through this partnership, FireMon will gain a wider reach, enabling businesses of all sizes to access its advanced security solutions, while Climb Channel Solutions will expand its portfolio to offer comprehensive cybersecurity services to its resellers. "Teaming up with FireMon aligns perfectly with our commitment to providing innovative, reliable and cybersecurity technology solutions to our reseller partners," says Dale Foster, CEO of Climb Channel Solutions. "FireMon's visibility into and control over network security infrastructures will add significant value to our portfolio and help our resellers navigate the complex landscape of cybersecurity."

07:25 EDT Vital Farms expects to generate net revenue over $1B by end of 2027 - By the end of fiscal year 2027, management expects to generate annual net revenue of more than $1 billion in Vital Farms' current categories. Management expects gross margin of at least 35% of net revenue by fiscal year 2027. Management expects Adjusted EBITDA Margin in the range of 12% to 14% of net revenue by fiscal year 2027.

07:23 EDT Fortrea Holdings completes expansion of clinical pharmacology solutions - Fortrea announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin. "The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data," said Oren Cohen, M.D., Fortrea's president of Clinical Pharmacology and chief medical officer. "Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them."

07:21 EDT Eyenovia announces FDA approval of adding Coastline as contract manufacturer - Eyenovia announced that the FDA has approved Eyenovia's Supplemental New Drug Application, sNDA, adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis. "One of the many benefits of Mydcombi is that, unlike eye droppers, there is no protruding tip that can come in contact with the patient's eye. In many applications today, eyecare institutions and surgeons are discarding bottles after each use to prevent this risk of cross-contamination, creating waste and unnecessary expense," stated Michael Rowe, chief executive officer of Eyenovia. "We believe Mydcombi, because of its design, addresses this challenge and can provide significant cost savings to doctors and surgical centers. With FDA approval of Coastline, our manufacturing capabilities are in place, and we anticipate initiating Mydcombi commercial production imminently with the goal of having product available to ship in January of 2024."

07:18 EDT Starbucks optimistic about China despite market headwinds

07:16 EDT BioCryst sees FY23 global net ORLADEYO revenue no less than $320M - The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. The company continues to be disciplined in its approach to capital allocation and is reducing its outlook for operating expenses for full year 2023, not including non-cash stock compensation, to between $365 million and $375 million, reflecting an expected decline from 2022 operating expenses.

07:14 EDT Peloton says expect positive adjusted EBITDA in second half of FY24 - We had a solid Q1FY24 and performed at or above our guidance. We were able to focus our attention on the performance of the business, putting the negative surprises and distractions of past quarters in the rearview mirror. And as we customarily do each time this year, we've been preparing for the seasonal holiday rush and cementing important partnerships we expect to drive increased brand relevance and growth. These growth initiatives, which I'll discuss next, inform our performance expectations for 2HFY24. Our guidance forecasts a return to revenue growth in 2H. We also expect positive adjusted EBITDA and substantial positive free cash flow* in the second half of this fiscal year, with a goal of achieving near breakeven free cash flow on a full year basis.

07:08 EDT Starbucks to update on LT strategies, provide FY24 guidance this afternoon

07:05 EDT Starbucks: 'We have great momentum,' fueled largely by reinvention plan - Comments taken from Q4 earnings conference call.

06:43 EDT Moderna sees $4B in sales in 2024, mostly in 2H - Moderna is projecting approximately $4 billion in sales in 2024, mostly in the second half of the year, primarily due to COVID-19 vaccine global sales and the launch of its RSV vaccine. In 2025, the Company expects to return to organic sales growth. The Company is projecting cost of sales as a percentage of sales to be approximately 35% in 2024, which is expected to improve with sales increasing in 2025. R&D expenses are expected to be approximately $4.5 billion in 2024 and flat to down in 2025. SG&A expenses are expected to be approximately $1.3 billion in 2024 and flat to down in 2025. Taxes are expected to be negligible in both 2024 and 2025. The Company expects capital expenditures to be approximately $0.9 billion in 2024 and materially lower in 2025, following the completion of manufacturing sites in Australia, Canada and the United Kingdom. Moderna expects to break even in 2026. The Company expects an ending cash balance of approximately $9 billion in 2024 and in the range of $6-7 billion in 2025.

06:42 EDT Moderna sees 2023 Spikevax sales of at least $6B

06:25 EDT Starbucks reports Q4 global SSS up 8% - Global comparable store sales increased 8%, driven by a 4% increase in average ticket and 3% increase in comparable transactions. North America and U.S. comparable store sales increased 8%, driven by a 6% increase in average ticket and 2% increase in comparable transactions. International comparable store sales increased 5%, driven by a 6% increase in comparable transactions and 1% decline in average ticket; China comparable store sales increased 5%, driven by an 8% increase in comparable transactions and a 3% decline in average ticket. The company opened 816 net new stores in Q4, ending the period with 38,038 stores: 52% company-operated and 48% licensed. At the end of Q4, stores in the U.S. and China comprised 61% of the company's global portfolio, with 16,352 and 6,806 stores in the U.S. and China, respectively

06:24 EDT Primo Water sells certain International businesses for $575M in cash - Primo Water entered into a definitive agreement whereby Culligan International will acquire Primo Water's International businesses, excluding the Aimia Foods, United Kingdom, Portugal, and Israel businesses, in an all-cash transaction valued at up to $575M. Upon closing the transaction, Primo Water intends to repay the outstanding balance of its cash flow revolver, with a long-term goal of sustaining adjusted net leverage under 2.5x adjusted EBITDA. Also, upon closing, an incremental $25M share repurchase will be authorized, revising the share repurchase authorization to $75M. The transaction is expected to close by December 31, subject to the receipt of regulatory approvals and the satisfaction of other customary closing conditions.

06:05 EDT Six Flags, Cedar Fair to refinance revolving credit facilities - The merger is expected to close in the first half of 2024, following receipt of Six Flags (SIX) shareholder approval, regulatory approvals, and satisfaction of customary closing conditions. Approval by Cedar Fair (FUN) unitholders is not required. Six Flags' largest shareholder, which owns approximately 13.6% of Six Flags' shares outstanding, has signed a voting and support agreement to vote in favor of the transaction. The transaction is not expected to trigger any change of control provision under Cedar Fair's and Six Flags' respective outstanding Notes. The companies expect to refinance their respective revolving credit facilities, and Six Flags expects to refinance the Six Flags Term Loan, ahead of transaction close.

06:04 EDT Combined Cedar Fair, Six Flags to have pro forma enterprise value of $8B

06:02 EDT Cedar Fair, Six Flags to combine in merger of equals transaction

05:27 EDT Shell sees FY23 cash capital expenditures $23B-$25B

05:13 EDT InterDigital signs new multi-year royalty-bearing global license with Lenovo - InterDigital announced that it has signed a new multi-year royalty-bearing global license with Lenovo covering InterDigital's HEVC video patents. The new license brings to an end all related HEVC litigation between the two companies.

05:09 EDT Stagwell acquires Movers+Shakers, terms undisclosed - Stagwell has acquired Movers+Shakers. The agency will join Stagwell's Constellation network of agencies, which includes 72andSunny, Instrument, The Harris Poll, and others. Movers+Shakers has 250B campaign views to date. New business momentum includes 21 new clients in 2023, including being named social media and culture agency of record for Tinder, and creative and culture agency of record for Elemis. Terms of the deal were not disclosed.